Carien Creutzberg
Hoogleraar Radiotherapie van gynaecologische tumoren
- Naam
- Prof.dr. C.L. Creutzberg
- Telefoon
- +31 71 526 5120
- c.l.creutzberg@lumc.nl
Carien Creutzberg is hoogleraar Radiotherapie en als radiotherapeut-oncoloog verbonden aan de afdeling Radiotherapie van het Leids Universitair Medisch Centrum. Ze heeft zich zowel in de patiëntenzorg als in klinisch-wetenschappelijk onderzoek vooral gespecialiseerd in de behandeling van vrouwen met gynaecologische kanker. Daarnaast bekleedt ze diverse nationale en internationale wetenschappelijke functies zoals lid van de KWF Adviesraad, bestuurslid van de Dutch Gynaecological Oncology Group en senior editor van het International Journal of Gynecological Cancer.
Meer informatie over Carien Creutzberg
Carien Creutzberg is hoogleraar Radiotherapie en als radiotherapeut-oncoloog verbonden aan de afdeling Radiotherapie van het Leids Universitair Medisch Centrum. Ze heeft zich zowel in de patiëntenzorg als in klinisch-wetenschappelijk onderzoek vooral gespecialiseerd in de behandeling van vrouwen met gynaecologische kanker. Daarnaast bekleedt ze diverse nationale en internationale wetenschappelijke functies zoals lid van de KWF Adviesraad, bestuurslid van de Dutch Gynaecological Oncology Group en senior editor van het International Journal of Gynecological Cancer.
Radiotherapie
De behandeling van vrouwen met gynaecologische kanker omvat vaak een combinatie van operatie, radiotherapie en/of chemotherapie. Deze behandeling kan een grote invloed hebben op het verdere leven van vrouwen met gynaecologische kanker, zoals baarmoederkanker (endometriumcarcinoom) of baarmoederhalskanker (cervixcarcinoom). Al ruim 25 jaar doet Carien Creutzberg onderzoek naar verbetering van de behandelingsresultaten, vermindering van bijwerkingen, verbetering van de kwaliteit van leven en naar de eigenschappen van deze kankertypes. Ze is hoofdonderzoeker van de vier opeenvolgende PORTEC-trials, die in nationaal en internationaal verband zijn uitgevoerd en die wereldwijd invloed op de behandeling van endometriumcarcinoom hebben gehad. Daarnaast doet ze samen met Prof Vincent Smit en dr Tjalling Bosse van de afdeling Pathologie translationeel onderzoek naar de klinische en moleculair-genetische eigenschappen van endometriumcarcinoom. Doel is om het gedrag van de individuele tumoren beter te voorspellen en de (na)behandeling hierop af te stemmen, zodat de behandeling meer op maat is en minder vrouwen onnodig worden behandeld. Voor internationale samenwerking in translationeel onderzoek werd het TransPORTEC Consortium opgericht. Voorts doet Creutzberg samen met dr Ter Kuile van de afdeling gynaecologie/seksuologie onderzoek naar ondersteuning van de seksuele rehabilitatie van vrouwen na radiotherapie voor baarmoederhalskanker, om hun herstel en kwaliteit van leven te verbeteren. Ze begeleidt meerdere promovendi op de afdelingen radiotherapie, pathologie en seksuologie.
Carien Creutzberg heeft meer dan 110 artikelen in wetenschappelijke tijdschriften en 10 hoofdstukken in leerboeken gepubliceerd. Ze is lid van de KWF Adviesraad, lid van het Concilium van de Nederlandse Vereniging voor Radiotherapie en Oncologie, mede-oprichter en bestuurslid van de Dutch Gynaecological Oncology Group, co-chair van de Endometrial Committee van de Gynaecological Cancer InterGroup, lid van de Scientific Committee voor het 2018 International Gynecological Cancer Society congres, lid van de Gynaecological Cancer Track van de European Society of Medical Oncology en senior editor van het International Journal of Gynecological Cancer.
Tot november 2017 was zij lid van de Council van de European Society of Gynaecological Oncology ESGO, voorzitter van de ESGO Scientific Committee en co-chair van de ESMO-ESGO-ESTRO consensus meeting over behandeling van endometriumcarcinoom. In het verleden was ze o.a. lid van de Council van de International Gynecological Cancer Society, voorzitter van de wetenschapscommissie van de NVRO en lid van de NCI Uterine Corpus Cancer Task Force. Ze is regelmatig spreker op internationale wetenschappelijke congressen over gynaecologische oncologie, klinische oncologie en radiotherapie.
Wetenschappelijke carrière
Carien Creutzberg studeerde Geneeskunde aan de Universiteit Leiden, waar ze in 1987 haar artsexamen behaalde (cum laude). Ze specialiseerde zich in Radiotherapie in het ErasmusMC Kankercentrum in Rotterdam, waar ze van 1993-2000 als radiotherapeut-oncoloog werkzaam was en in 1998 promoveerde op het proefschrift ‘Treatment verification in Radiation Oncology – portal imaging in clinical practice’.
Carien Creutzberg is sinds 2000 verbonden als radiotherapeut-oncoloog, klinisch onderzoeker en plaatsvervangend opleider Radiotherapie aan het Leids Universitair Medisch Centrum. Ze werd in 2012 benoemd als hoogleraar. De titel van haar oratie is ‘Over leven, lijden en leiden’.
Prijzen en eervolle benoemingen
Voor haar klinische studies en gerelateerde translationele en rehabilitatie studies heeft Carien Creutzberg subsidies van KWF Kankerbestrijding ontvangen, en samen met buitenlandse collega’s ontving zij subsidies van Cancer Research UK en de Australische National Health Medical Research Council voor hun deelname aan de PORTEC-3 studie en radiotherapie studies naar kwaliteitscontrole en verbetering.
In 1999 ontving ze de IGCS Award for the best oral presentation.
Hoogleraar Radiotherapie van gynaecologische tumoren
- Faculteit Geneeskunde
- Divisie 2
- Radiologie
- Fremond, S.; Andani, S.; Wolf, J.B.; Dijkstra, J.; Melsbach, S.; Jobsen, J.J.; Brinkhuis, M.; Roothaan, S.; Jurgenliemk-Schulz, I.; Lutgens, L.C.H.W.; Nout, R.A.; Steen-banasik, E.M. van der; Boer, S.M. de; Powell, M.E.; Singh, N.; Mileshkin, L.R.; Mackay, H.J.; Leary, A.; Nijman, H.W.; Smit, V.T.H.B.M.; Creutzberg, C.L.; Horeweg, N.; Koelzer, V.H. & Bosse, T. (2023), Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts, The Lancet Digital Health 5(2): e71-e82.
- Vermij, L.; Jobsen, J.J.; Leon-Castillo, A.; Brinkhuis, M.; Roothaan, S.; Powell, M.E.; Boer, S.M. de; Khaw, P.; Mileshkin, L.R.; Fyles, A.; Leary, A.; Genestie, C.; Jnrgenliemk-Schulz, I.M.; Crosbie, E.J.; Mackay, H.J.; Nijman, H.W.; Nout, R.A.; Smit, V.T.H.B.M.; Creutzberg, C.L.; Horeweg, N.; Bosse, T.; Boer, S.M. de & TransPORTEC Consortium (2023), Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry, British Journal of Cancer 128(7): 1360-1368.
- (2023), Predictive factors for toxicity after primary chemoradiation for locally advanced cervical cancer: a systematic review, International Journal of Radiation Oncology - Biology - Physics.
- Bosse, T.; Creutzberg, C.L.; Crosbie, E.J.; Han, K.; Horeweg, N.; Leary, A.; Kroep, J.R.; McAlpine, J.N.; Powell, M.E.; Blanc-Durand, F.; Bruyn, M. de; Church, D.N.; Koelzer, V.H.; Kommoss, S.; Singh, N.; Bardet, A.; Counsell, N.; Putter, H.; Tu, D.; Edmondson, R.; Gordon, C.; Ledermann, J.; Morice, P.; MacKay, H.; Nijman, H.; Nout, R.A.; Smit, V.T.H.B.M.; White, H.; Alexandre, J.; Boer, S.M. de; Boere, I.; Cooper, R.; Ethier, J.L.; Frenel, J.S.; McGrane, J.; Taylor, A.; Welch, S.; Westermann, A.M.; Linden, H.D. van der; Farrelly, L.; Feeney, A.; Kaya, M.; Liu, W.; Melis, A.; Ngadjeua-Tchouatieu, F.; Parulekar, W.; Verhoeven-Adema, K. & RAINBO Res Consortium (2023), Refining adjuvant treatment in endometrial cancer based on molecular features, International Journal of Gynecological Cancer 33(1): 109-117.
- Vermij, L.; Leon-Castillo, A.; Singh, N.; Powell, M.E.; Edmondson, R.J.; Genestie, C.; Khaw, P.; Pyman, J.; McLachlin, C.M.; Ghatage, P.; Boer, S.M. de; Nijman, H.W.; Smit, V.T.H.B.M.; Crosbie, E.J.; Leary, A.; Creutzberg, C.L.; Horeweg, N.; Bosse, T. & TransPORTEC Consortium (2022), p53 immunohistochemistry in endometrial cancer, Modern Pathology 35(10): 1475-1483.
- Wu, J.Q.; Horeweg, N.; Bruyn, M. de; Nout, R.A.; Jurgenliemk-Schulz, I.M.; Lutgens, L.C.H.W.; Jobsen, J.J.; Steen-Banasik, E.M. van der; Nijman, H.W.; Smit, V.T.H.B.M.; Bosse, T.; Creutzberg, C.L. & Koelzer, V.H. (2022), Automated causal inference in application to randomized controlled clinical trials, Nature Machine Intelligence 4(5): 436-+.
- Horeweg, N.; Workel, H.H.; Loiero, D.; Church, D.N.; Vermij, L.; Leon-Castillo, A.; Krog, R.T.; Boer, S.M. de; Nout, R.A.; Powell, M.E.; Mileshkin, L.R.; MacKay, H.; Leary, A.; Singh, N.; Jurgenliemk-Schulz, I.M.; Smit, V.T.H.B.M.; Creutzberg, C.L.; Koelzer, V.H.; Nijman, H.W.; Bosse, T. & Bruyn, M. de (2022), Tertiary lymphoid structures critical for prognosis in endometrial cancer patients, Nature Communications 13(1).
- Leon-Castillo, A.; Horeweg, N.; Peters, E.E.M.; Rutten, T.; Haar, N. ter; Smit, V.T.H.B.M.; Kroon, C.D.; Boennelycke, M.; Hogdall, E.; Hogdall, C.; Nout, R.R.A.; Creutzberg, C.L.; Ortoft, G. & Bosse, T. (2022), Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment, Gynecologic Oncology 164(3).
- Khaw, P.; , V. do; Lim, K.; Cunninghame, J.; Dixon, J.; Vassie, J.; Bailey, M.; Johnson, C.; Kahl, K.; Gordon, C.; Cook, O.; Foo, K.; Fyles, A.; Powell, M.; Haie-Meder, C.; D'Amico, R.; Bessette, P.; Mileshkin, L.; Creutzberg, C.L. & Moore, A. (2022), Radiotherapy quality assurance in the PORTEC-3 (TROG 08.04) trial, Clinical Oncology 34(3): 198-204.
- Wortman, B.G.; Post, C.C.B.; Powell, M.E.; Khaw, P.; Fyles, A.; D'Amico, R.; Haie-Meder, C.; Jurgenliemk-Schulz, I.M.; McCormack, M.; , V. do; Katsaros, D.; Bessette, P.; Baron, M.H.; Nout, R.A.; Whitmarsh, K.; Mileshkin, L.; Lutgens, L.C.H.W.; Kitchener, H.C.; Brooks, S.; Nijman, H.W.; Astreinidou, E.; Putter, H.; Creutzberg, C.L. & Boer, S.M. de (2022), Radiation therapy techniques and treatment-related toxicity in the PORTEC-3 trial, International Journal of Radiation Oncology - Biology - Physics 112(2): 390-399.
- Heerik, A.S.V.M.V.; Aiyer, K.T.S.; Stelloo, E.; Juergenliemk-Schulz, I.M.; Lutgens, L.C.H.W.; Jobsen, J.J.; Mens, J.W.M.; Steen-banasik, E.M. van der; Creutzberg, C.L.; Smit, V.T.H.B.M.; Horeweg, N. & Bosse, T. (2022), Microcystic elongated and fragmented (MELF) pattern of invasion, Gynecologic Oncology 166(3): 530--537.
- D G, CL C & A J (2022), Special Issue: Radiation Oncology in Gynecologic Malignancies., International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
- Heerik, A.S.V.M. van den; Horeweg, N.; Creutzberg, C.L. & Nout, R.A. (2022), Vaginal brachytherapy management of stage I and II endometrial cancer, International Journal of Gynecological Cancer.
- Suvaal, I.; Hummel, S.B.; Mens, J.W.M.; Doorn, H.C. van; Hout, W.B. van den; Creutzberg, C.L. & Kuile, M.M. ter (2021), A sexual rehabilitation intervention for women with gynaecological cancer receiving radiotherapy (SPARC study), BMC Cancer 21(1).
- Oonk, M.H.M.; Slomovitz, B.; Baldwin, P.J.W.; Doorn, H.C. van; Velden, J. van der; Hullu, J.A. de; Gaarenstroom, K.N.; Slangen, B.F.M.; Vergote, I.; Brannstrom, M.; Dorst, E.B.L. van; Driel, W.J. van; Hermans, R.H.; Nunns, D.; Widschwendter, M.; Nugent, D.; Holland, C.M.; Sharma, A.; DiSilvestro, P.A.; Mannel, R.; Boll, D.; Cibula, D.; Covens, A.; Provencher, D.; Runnebaum, I.B.; Luesley, D.; Ellis, P.; Duncan, T.J.; Tjiong, M.Y.; Cruickshank, D.J.; Kjolhede, P.; Levenback, C.F.; Bouda, J.; Kieser, K.E.; Palle, C.; Spirtos, N.M.; O'Malley, D.M.; Leitao, M.M.; Geller, M.A.; Dhar, K.; Asher, V.; Tamussino, K.; Tobias, D.H.; Borgfeldt, C.; Lea, J.S.; Bailey, J.; Lood, M.; Eyjolfsdottir, B.; Attard-Montalto, S.; Tewari, K.S.; Manchanda, R.; Jensen, P.T.; Persson, P.; , L. van le; Putter, H.; Bock, G.H. de; Monk, B.J.; Creutzberg, C.L. & Zee, A.G.J. van der (2021), Radiotherapy versus inguinofemoral lymphadenectomy as treatment for vulvar cancer patients with micrometastases in the sentinel node, Journal of Clinical Oncology 39(32): 3623-+.
- Corbeau, A.; Nout, R.A.; Mens, J.W.M.; Horeweg, N.; Godart, J.; Kerkhof, E.M.; Kuipers, S.C.; Poelgeest, M.I.E. van; Kroep, J.R.; Boere, I.A.; Doorn, H.C. van; Hoogeman, M.S.; Heide, U.A. van der; Putter, H.; Welters, M.J.P.; Burg, S.H. van der; Creutzberg, C.L. & Boer, S.M. de (2021), PROTECT: prospective phase-II-trial evaluating adaptive proton therapy for cervical cancer to reduce the impact on morbidity and the immune system, Cancers 13(20).
- Koskas, M.; Amant, F.; Mirza, M.R. & Creutzberg, C.L. (2021), Cancer of the corpus uteri: 2021 update, International Journal of Gynecology & Obstetrics 155: 45-60.
- Triest, B. van; Rasing, M.; Velden, J. van der; Hullu, J. de; Witteveen, P.O.; Beukema, J.C.; Steen-Banasik, E. van der; Westerveld, H.; Snyers, A.; Peters, M.; Creutzberg, C.L.; Nout, R.A.; Lutgens, L. & Jurgenliemk-Schulz, I. (2021), Phase II study of definitive chemoradiation for locally advanced squamous cell cancer of the vulva: An efficacy study, Gynecologic Oncology 163(1): 117-124.
- Post, C.; Stelloo, E.; Smit, V.; Ruano, D.; Tops, C.M.; Vermij, L.; Rutten, T.A.; Jurgenliemk-Schulz, I.M.; Lutgens, L.C.; Jobsen, J.J.; Nout, R.A.; Crosbie, E.J.; Powell, M.E.; Mileshkin, L.; Leary, A.; Bessette, P.; Boer, S.M. de; Horeweg, N.; Wezel, T. van; Bosse, T. & Creutzberg, C.L. (2021), Prevalence and prognosis of Lynch syndrome and sporadic mismatch repair deficiency in endometrial cancer, Journal of the National Cancer Institute 113(9).
- Greimel, E.; Nagele, E.; Lanceley, A.; Oberguggenberger, A.S.; Nordin, A.; Kuljanic, K.; Arraras, J.I.; Chie, W.C.; Jensen, P.T.; Tomaszewski, K.A.; Creutzberg, C.L.; Galalae, R.; Toelen, H.; Zimmermann, K.; Bjelic-Radisic, V.; Costantini, A.; Almont, T.; Serpentini, S.; Froding, L.P.; Vistad, I.; Schmalz, C. & EORTC Quality Life Grp (2021), Psychometric validation of the European Organisation for Research and Treatment of Cancer-Quality of Life Questionnaire Sexual Health (EORTC QLQ-SH22), European Journal of Cancer 154: 235-245.
- Post, C.C.B.; Mens, J.W.M.; Haverkort, M.A.D.; Koppe, F.; Jurgenliemk-Schulz, I.M.; Snyers, A.; Roeloffzen, E.M.A.; Schaake, E.E.; Slot, A.; Stam, T.C.; Beukema, J.C.; Berg, H.A. van den; Lutgens, L.C.H.W.; Nijman, H.W.; Kroon, C.D. de; Kroep, J.R.; Stiggelbout, A.M. & Creutzberg, C.L. (2021), Patients' and clinicians' preferences in adjuvant treatment for high-risk endometrial cancer, Gynecologic Oncology 161(3).
- Concin, N.; Matias-Guiu, X.; Creutzberg, C.L. & ESGO-ESTRO-ESP Endometrial (2021), Response to: Are we confident treating pT1a G1 lymphovascular space invasion-negative patients (with myometrial invasion) with chemoradiotherapy on the basis of p53abn?
- Zayed, S.; Nguyen, T.K.; Lin, C.; Boldt, G.; Beriwal, S.; Creutzberg, C.L.; Kamrava, M.; Mendez, L.C.; Velker, V.; Doll, C.; Taggar, A.; Leung, E. & D'Souza, D.P. (2021), Red blood cell transfusion practices for patients with cervical cancer undergoing radiotherapy, Jama Network Open 4(4).
- Heerik, A.S.V.M. van den; Horeweg, N.; Boer, S.M. de; Bosse, T. & Creutzberg, C.L. (2021), Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy, International Journal of Gynecological Cancer 31(4): 594-604.
- Westerveld, H.; Schmid, M.P.; Nout, R.A.; Chargari, C.; Pieters, B.R.; Creutzberg, C.L.; Sturdza, A.; Lindegaard, J.C.; Kesteren, Z. van; Mazeron, R.; Nesvacil, N. & Fokdal, L.U. (2021), Image-guided adaptive brachytherapy (IGABT) for primary vaginal cancer, Cancers 13(6).
- Post, C.C.B.; Boer, S.M. de; Powell, M.E.; Mileshkin, L.; Katsaros, D.; Bessette, P.; Haie-Meder, C.; Ottevanger, N.P.B.; Ledermann, J.A.; Khaw, P.; D'Amico, R.; Fyles, A.; Baron, M.H.; Kitchener, H.C.; Nijman, H.W.; Lutgens, L.C.H.W.; Brooks, S.; Jurgenliemk-Schulz, I.M.; Feeney, A.; Goss, G.; Fossati, R.; Ghatage, P.; Leary, A.; , V. do; Lissoni, A.A.; McCormack, M.; Nout, R.A.; Verhoeven-Adema, K.W.; Smit, V.T.H.B.M.; Putter, H. & Creutzberg, C.L. (2020), Long-term toxicity and health-related quality of life after adjuvant chemoradiation therapy or radiation therapy alone for high-risk endometrial cancer in the randomized PORTEC-3 trial., International journal of radiation oncology, biology, physics 109(4).
- Post, C.C.B.; Boer, S.M. de; Powell, M.E.; Mileshkin, L.; Katsaros, D.; Bessette, P.; Haie-Meder, C.; Ottevanger, N.P.B.; Ledermann, J.A.; Khaw, P.; D'Amico, R.; Fyles, A.; Baron, M.H.; Kitchener, H.C.; Nijman, H.W.; Lutgens, L.C.H.W.; Brooks, S.; Jurgenliemk-Schulz, I.M.; Feeney, A.; Goss, G.; Fossati, R.; Ghatage, P.; Leary, A.; , V. do; Lissoni, A.A.; McCormack, M.; Nout, R.A.; Verhoeven-Adema, K.W.; Smit, V.T.H.B.M.; Putter, H. & Creutzberg, C.L. (2021), Long-term toxicity and health-related quality of life after adjuvant chemoradiation therapy or radiation therapy alone for high-risk endometrial cancer in the randomized PORTEC-3 trial, International Journal of Radiation Oncology - Biology - Physics 109(4): 975-986.
- Concin, N.; Creutzberg, C.L.; Vergote, I.; Cibula, D.; Mirza, M.R.; Marnitz, S.; Ledermann, J.A.; Bosse, T.; Chargari, C.; Fagotti, A.; Fotopoulou, C.; Gonzalez-Martin, A.; Lax, S.F.; Lorusso, D.; Marth, C.; Morice, P.; Nout, R.A.; O'Donnell, D.E.; Querleu, D.; Raspollini, M.R.; Sehouli, J.; Sturdza, A.E.; Taylor, A.; Westermann, A.M.; Wimberger, P.; Colombo, N.; Planchamp, F. & Matias-Guiu, X. (2021), ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma., Virchows Archiv : an international journal of pathology 478.
- Wortman, B.G.; Astreinidou, E.; Laman, M.S.; Steen-Banasik, E.M. van der; Lutgens, L.C.H.W.; Westerveld, H.; Koppe, F.; Slot, A.; Berg, H.A. van den; Nowee, M.E.; Bijmolt, S.; Stam, T.C.; Zwanenburg, A.G.; Mens, J.W.M.; Jurgenliemk-Schulz, I.M.; Snyers, A.; Gillham, C.M.; Weidner, N.; Kommoss, S.; Vandecasteele, K.; Tomancova, V.; Creutzberg, C.L.; Nout, R.A. & PORTEC Study Grp (2020), Brachytherapy quality assurance in the PORTEC-4a trial for molecular-integrated risk profile guided adjuvant treatment of endometrial cancer., Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 155.
- Small, W.; Bosch, W.R.; Harkenrider, M.M.; Strauss, J.B.; Abu-Rustum, N.; Albuquerque, K.V.; Beriwal, S.; Creutzberg, C.L.; Eifel, P.J.; Erickson, B.A.; Fyles, A.W.; Hentz, C.L.; Jhingran, A.; Klopp, A.H.; Kunos, C.A.; Mell, L.K.; Portelance, L.; Powell, M.E.; Viswanathan, A.N.; Yacoub, J.H.; Yashar, C.M.; Winter, K.A. & Gaffney, D.K. (2020), NRG oncology/RTOG consensus guidelines for delineation of clinical target volume for intensity modulated pelvic radiation therapy in postoperative treatment of endometrial and cervical cancer, International journal of radiation oncology, biology, physics 109(2).
- Concin, N.; Matias-Guiu, X.; Vergote, I.; Cibula, D.; Mirza, M.R.; Marnitz, S.; Ledermann, J.; Bosse, T.; Chargari, C.; Fagotti, A.; Fotopoulou, C.; Martin, A.G.; Lax, S.; Lorusso, D.; Marth, C.; Morice, P.; Nout, R.A.; O'Donnell, D.; Querleu, D.; Raspollini, M.R.; Sehouli, J.; Sturdza, A.; Taylor, A.; Westermann, A.; Wimberger, P.; Colombo, N.; Planchamp, F. & Creutzberg, C.L. (2021), ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 154.
- Wortman, B.G.; Astreinidou, E.; Laman, M.S.; Steen-Banasik, E.M. van der; Lutgens, L.C.H.W.; Westerveld, H.; Koppe, F.; Slot, A.; Berg, H.A. van den; Nowee, M.E.; Bijmolt, S.; Stam, T.C.; Zwanenburg, A.G.; Mens, J.W.M.; Jurgenliemk-Schulz, I.M.; Snyers, A.; Gillham, C.M.; Weidner, N.; Kommoss, S.; Vandecasteele, K.; Tomancova, V.; Creutzberg, C.L.; Nout, R.A. & PORTEC Study Grp (2021), Brachytherapy quality assurance in the PORTEC-4a trial for molecular-integrated risk profile guided adjuvant treatment of endometrial cancer, Radiotherapy & Oncology 155: 160--166.
- CCB P, JWM M, MAD H, F K, IM J, A S, EMA R, EE S, A S, TC S, JC B & CL C (2021), Patients' and clinicians' preferences in adjuvant treatment for high-risk endometrial cancer: Implications for shared decision making., Gynecologic Oncology.
- BG W, CCB P, ME P, P K, A F, R D, C H, IM J, M M, V D, D K, P B & de Boer SM (2021), Radiation Therapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of 3-Dimensional Conformal Radiation Therapy Versus Intensity-Modulated Radiation Therapy., International journal of radiation oncology, biology, physics.
- EEM P, A L, E H, M B, VTHBM S, C H, CL C, T B, RA N & G Ø (2021), Substantial Lymphovascular Space Invasion Is an Adverse Prognostic Factor in High-risk Endometrial Cancer., International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
- Vermij, L.; Horeweg, N.; Leon-Castillo, A.; Rutten, T.A.; Mileshkin, L.R.; Mackay, H.J.; Leary, A.; Powell, M.E.; Singh, N.; Crosbie, E.J.; Smit, V.T.H.B.M.; Creutzberg, C.L. & Bosse, T. (2020), HER2 status in high-risk endometrial cancers (PORTEC-3), Cancers 2021(1).
- Concin, N.; Matias-Guiu, X.; Vergote, I.; Cibula, D.; Mirza, M.R.; Marnitz, S.; Ledermann, J.; Bosse, T.; Chargari, C.; Fagotti, A.; Fotopoulou, C.; Martin, A.G.; Lax, S.; Lorusso, D.; Marth, C.; Morice, P.; Nout, R.A.; O'Donnell, D.; Querleu, D.; Raspollini, M.R.; Sehouli, J.; Sturdza, A.; Taylor, A.; Westermann, A.; Wimberger, P.; Colombo, N.; Planchamp, F. & Creutzberg, C.L. (2020), ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma., International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2021(31).
- Akker, M.J.E. van den; Horeweg, N.; Beltman, J.J.; Creutzberg, C.L. & Nout, R.A. (2020), Efficacy and toxicity of postoperative external beam radiotherapy or chemoradiation for early-stage cervical cancer, International Journal of Gynecological Cancer 30(12): 1878-1886.
- Horeweg, N.; Bruyn, M. de; Nout, R.A.; Stelloo, E.; Kedziersza, K.; Leon-Castillo, A.; Plat, A.; Mertz, K.D.; Osse, M.; Jurgenliemk-Schulz, I.M.; Lutgens, L.C.H.W.; Jobsen, J.J.; Steen-Banasik, E.M. van der; Smit, V.T.; Creutzberg, C.L.; Bosse, T.; Nijman, H.W.; Koelzer, V.H. & Church, D.N. (2020), Prognostic integrated image-based immune and molecular profiling in early-stage endometrial cancer, Cancer Immunology Research 8(12): 1508-1519.
- Kortekaas, K.E.; Bastiaannet, E.; Doorn, H.C. van; Steenwijk, P.J.D. van; Ewing-Graham, P.C.; Creutzberg, C.L.; Akdeniz, K.; Nooij, L.S.; Burg, S.H. van der; Bosse, T. & Poelgeest, M.I.E. van (2020), Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes, Gynecologic Oncology 159(3): 649-656.
- Leon-Castillo, A.; Boer, S.M. de; Powell, M.E.; Mileshkin, L.R.; Mackay, H.J.; Leary, A.; Nijman, H.W.; Singh, N.; Pollock, P.M.; Bessette, P.; Fyles, A.; Haie-Meder, C.; Smit, V.T.H.B.M.; Edmondson, R.J.; Putter, H.; Kitchener, H.C.; Crosbie, E.J.; Bruyn, M. de; Nout, R.A.; Horeweg, N.; Creutzberg, C.L.; Bosse, T. & TransPORTEC Consortium (2020), Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer, Journal of Clinical Oncology 38(29): 3388-+.
- Heerik, A.S.V.M. van den; Horeweg, N.; Nout, R.A.; Lutgens, L.C.H.W.; Steen-banasik, E.M. van der; Westerveld, G.H.; Berg, H.A. van den; Slot, A.; Koppe, F.L.A.; Kommoss, S.; Mens, J.W.M.; Nowee, M.E.; Bijmolt, S.; Cibula, D.; Stam, T.C.; Jurgenliemk-Schulz, I.M.; Snyers, A.; Hamann, M.; Zwanenburg, A.G.; Coen, V.L.M.A.; Vandecasteele, K.; Gillham, C.; Chargari, C.; Verhoeven-Adema, K.W.; Putter, H.; Hout, W.B. van den; Wortman, B.G.; Nijman, H.W.; Bosse, T. & Creutzberg, C.L. (2020), PORTEC-4a, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2020(30).
- Heerik, A.S.V.M. van den; Horeweg, N.; Boer, S.M. de; Bosse, T. & Creutzberg, C.L. (2020), Adjuvant therapy for endometrial cancer in the era of molecular classification, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2021(34).
- Post, C.C.B.; Westermann, A.M.; Bosse, T.; Creutzberg, C.L. & Kroep, J.R. (2020), PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer, Critical Reviews in Oncology/Hematology 152.
- Brouwer, N.J.; Marinkovic, M.; Peters, F.P.; Hulshof, M.C.C.M.; Pieters, B.R.; Keizer, R.J.W. de; Horeweg, N.; Laman, M.S.; Bleeker, J.C.; Duinen, S.G. van; Jager, M.J.; Creutzberg, C.L. & Luyten, G.P.M. (2020), Management of conjunctival melanoma with local excision and adjuvant brachytherapy, Eye 35.
- Akker, M.J.E. van den; Horeweg, N.; Beltman, J.J.; Creutzberg, C.L. & Nout, R.A. (2020), Efficacy and toxicity of postoperative external beam radiotherapy or chemoradiation for early-stage cervical cancer., International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
- L V, N H, A L, TA R, LR M, HJ M, A L, ME P, N S, EJ C, VTHBM S, CL C & T B (2020), HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes., Cancers.
- A L, de Boer SM, ME P, LR M, HJ M, A L, HW N, N S, PM P, P B, A F, C H & consortium T (2020), Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy., Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
- van den Heerik ASVM, N H, RA N, LCHW L, van der Steen-Banasik EM, GH W, van den Berg HA, A S, FLA K, S K & CL C (2020), PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer., International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
- Boer, S.M. de; Powell, M.E.; Mileshkin, L.; Katsaros, D.; Bessette, P.; Haie-Meder, C.; Ottevanger, P.B.; Ledermann, J.A.; Khaw, P.; D'Amico, R.; Fyles, A.; Baron, M.H.; Jurgenliemk-Schulz, I.M.; Kitchener, H.C.; Nijman, H.W.; Wilson, G.; Brooks, S.; Gribaudo, S.; Provencher, D.; Hanzen, C.; Kruitwagen, R.F.; Smit, V.T.H.B.M.; Singh, N.; , V. do; Lissoni, A.; Nout, R.A.; Feeney, A.; Verhoeven-Adema, K.W.; Putter, H.; Creutzberg, C.L. & PORTEC Study Grp (2019), Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial, The Lancet Oncology 20(9): 1273-1285.
- Wortman, B.G.; Nout, R.A.; Bosse, T. & Creutzberg, C.L. (2019), Selecting Adjuvant Treatment for Endometrial Carcinoma Using Molecular Risk Factors, Current Oncology Reports 21(9).
- Creutzberg, C.L.; Lu, K.H. & Fleming, G.F. (2019), Uterine Cancer: Adjuvant Therapy and Management of Metastatic Disease, Journal of Clinical Oncology 37(27): 2490-+.
- Boer, S.M. de; Powell, M.E.; Mileshkin, L.; Katsaros, D.; Bessette, P.; Haie-Meder, C.; Ottevanger, P.B.; Ledermann, J.A.; Khaw, P.; D'Amico, R.; Fyles, A.; Baron, M.H.; Jurgenliemk-Schulz, I.M.; Kitchener, H.C.; Nijman, H.W.; Wilson, G.; Brooks, S.; Gribaudo, S.; Provencher, D.; Hanzen, C.; Kruitwagen, R.F.; Smit, V.T.H.B.M.; Singh, N.; , V. do; Lissoni, A.; Nout, R.A.; Feeney, A.; Verhoeven-Adema, K.W.; Putter, H.; Creutzberg, C.L. & PORTEC Study Grp (2019), Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3), The Lancet Oncology 20(9).
- Workel, H.H.; Lubbers, J.M.; Arnold, R.; Prins, T.M.; Vlies, P. van der; Lange, K. de; Bosse, T.; Gool, I.C. van; Eggink, F.A.; Wouters, M.C.A.; Komdeur, F.L.; Slikke, E.C. van der; Creutzberg, C.L.; Kol, A.; Plat, A.; Glaire, M.; Church, D.N.; Nijman, H.W. & Bruyn, M. de (2019), A Transcriptionally Distinct CXCL13(+)CD103(+)CD8(+) T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer, Cancer Immunology Research 7(5): 784-796.
- Horeweg, N.; Creutzberg, C.L.; Rijkmans, E.C.; Laman, M.S.; Velema, L.A.; Coen, V.L.M.A.; Stam, T.C.; Kerkhof, E.M.; Kroep, J.R.; Kroon, C.D. de & Nout, R.A. (2019), Efficacy and toxicity of chemoradiation with image-guided adaptive brachytherapy for locally advanced cervical cancer, International Journal of Gynecological Cancer 29(2): 257-265.
- Boer, F.L.; Eikelder, M.L.G. ten; Kapiteijn, E.H.; Creutzberg, C.L.; Galaal, K. & Poelgeest, M.I.E. van (2019), Vulvar malignant melanoma: Pathogenesis, clinical behaviour and management: Review of the literature, Cancer Treatment Reviews 73: 91-103.
- Bagnoli, M.; Shi, T.Y.; Gourley, C.; Speiser, P.; Reuss, A.; Nijman, H.W.; Creutzberg, C.L.; Scholl, S.; Negrouk, A.; Brady, M.F.; Hasegawa, K.; Oda, K.; McNeish, I.A.; Kohn, E.C.; Oza, A.M.; MacKay, H.; Millan, D.; Bennett, K.; Scott, C. & Mezzanzanica, D. (2019), Gynecological cancers translational, research implementation, and harmonization, Cells 8(3).
- Boer, S.M. de; Nout, R.A.; Bosse, T. & Creutzberg, C.L. (2019), Adjuvant therapy for high-risk endometrial cancer: recent evidence and future directions, Expert Review of Anticancer Therapy 19(1): 51-60.
- Auguste, A.; Genestie, C.; Bruyn, M. de; Adam, J.; Formal, A. le; Drusch, F.; Pautier, P.; Crosbie, E.J.; MacKay, H.; Kitchener, H.C.; Powell, M.; Pollock, P.M.; Mileshkin, L.; Edmondson, R.J.; Nout, R.; Nijman, H.W.; Creutzberg, C.L.; Bosse, T. & Leary, A. (2018), Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative, Modern Pathology 31(12): 1851-1861.
- Wortman, B.G.; Bosse, T.; Nout, R.A.; Lutgens, L.C.H.W.; Steen-Banasik, E.M. van der; Westerveld, H.; Berg, H. van den; Slot, A.; Winter, K.A.J. de; Verhoeven-Adema, K.W.; Smit, V.T.H.B.M.; Creutzberg, C.L. & PORTEC Study Grp (2018), Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial, Gynecologic Oncology 151(1): 69-75.
- Wortman, B.G.; Creutzberg, C.L.; Putter, H.; Jurgenliemk-Schulz, I.M.; Jobsen, J.J.; Lutgens, L.C.H.W.; Steen-Banasik, E.M. van der; Mens, J.W.M.; Slot, A.; Kroese, M.C.S.; Triest, B. van; Nijman, H.W.; Stelloo, E.; Bosse, T.; Boer, S.M. de; Putten, W.L.J. van; Smit, V.T.H.B.M.; Nout, R.A. & PORTEC Study Grp (2018), Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy, British Journal of Cancer 119(9): 1067-1074.
- Amant, F.; Mirza, M.R.; Koskas, M. & Creutzberg, C.L. (2018), Cancer of the corpus uteri, International Journal of Gynecology & Obstetrics 143: 37-50.
- Greimel, E.; Lanceley, A.; Oberguggenberger, A.; Nordin, A.; Kuljanic, K.; Schmalz, C.; Arraras, J.I.; Chie, W.; Jensen, P.T.; Tomaszewski, K.A.; Creutzberg, C.L.; Galalae, R.; Toelen, H.; Inwald, E.C.; Bjelic-Radisic, V. & EORTC Quality Life Grp (2018), Differences in health care professionals' and cancer patients' views on sexual health issues, Psycho-Oncology 27(9): 2299-2302.
- Marinkovic, M.; Horeweg, N.; Laman, M.S.; Bleeker, J.C.; Ketelaars, M.; Peters, F.P.; Luyten, G.P.M. & Creutzberg, C.L. (2018), Ruthenium-106 brachytherapy for iris and iridociliary melanomas, British Journal of Ophthalmology 102(8): 1154-1159.
- Dostalek, L.; Avall-Lundqvist, E.; Creutzberg, C.L.; Kurdiani, D.; Ponce, J.; Dostalkova, I. & Cibula, D. (2018), ESGO Survey on Current Practice in the Management of Cervical Cancer, International Journal of Gynecological Cancer 28(6): 1226-1231.
- Gool, I.C. van; Rayner, E.; Osse, E.M.; Nout, R.A.; Creutzberg, C.L.; Tomlinson, I.P.M.; Church, D.N.; Smit, V.T.H.B.M.; Wind, N. de; Bosse, T. & Drost, M. (2018), Adjuvant Treatment for POLE Proofreading Domain-Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues, Clinical Cancer Research 24(13): 3197-3203.
- Creutzberg, C.L. & Bosse, T. (2018), Molecular risk stratification to direct therapy in endometrial cancer: ready for the clinic?, Annals of Oncology 29(5): 1081-1082.
- Nout, R.A.; Powell, M.E.; Boer, S.M. de & Creutzberg, C.L. (2018), Treatment toxicity in endometrial cancer: can we identify and manage it better?, The Lancet Oncology 19(5): 602-602.
- Ezendam, N.P.M.; Rooij, B.H. de; Kruitwagen, R.F.P.M.; Creutzberg, C.L.; Loon, I. van; Boll, D.; Vos, M.C. & Poll-Franse, L.V. van de (2018), ENdometrial cancer SURvivors' follow-up carE (ENSURE): Less is more? Evaluating patient satisfaction and cost-effectiveness of a reduced follow-up schedule: study protocol of a randomized controlled trial, Trials 19.
- Boer, S.M. de; Powell, M.E.; Mileshkin, L.; Katsaros, D.; Bessette, P.; Haie-Meder, C.; Ottevanger, P.B.; Ledermann, J.A.; Khaw, P.; Colombo, A.; Fyles, A.; Baron, M.H.; Jurgenliemk-Schulz, I.M.; Kitchener, H.C.; Nijman, H.W.; Wilson, G.; Brooks, S.; Carinelli, S.; Provencher, D.; Hanzen, C.; Lutgens, L.C.H.W.; Smit, V.T.H.B.M.; Singh, N.; , V. do; D'Amico, R.; Nout, R.A.; Feeney, A.; Verhoeven-Adema, K.W.; Putter, H.; Creutzberg, C.L. & PORTEC Study Grp (2018), Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial, Lancet Oncology 19(3): 295-309.
- Oberguggenberger, A.S.; Nagele, E.; Inwald, E.C.; Tomaszewski, K.; Lanceley, A.; Nordin, A.; Creutzberg, C.L.; Kuljanic, K.; Kardamakis, D.; Schmalz, C.; Arraras, J.; Costantini, A.; Almont, T.; Wei-Chu, C.; Dehandschutter, S.; Winters, Z.; Greimel, E. & EORTC Quality Life Grp (2018), Phase 1-3 of the cross-cultural development of an EORTC questionnaire for the assessment of sexual health in cancer patients: the EORTC SHQ-22, Cancer Medicine 7(3): 635-645.
- Boer, S.M. de; Wortman, B.G.; Bosse, T.; Powell, M.E.; Singh, N.; Hollema, H.; Wilson, G.; Chowdhury, M.N.; Mileshkin, L.; Pyman, J.; Katsaros, D.; Carinelli, S.; Fyles, A.; McLachlin, C.M.; Haie-Meder, C.; Duvillard, P.; Nout, R.A.; Verhoeven-Adema, K.W.; Putter, H.; Creutzberg, C.L.; Smit, V.T.H.B.M. & PORTEC Study Grp (2018), Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer, Annals of Oncology 29(2): 424-430.
- Poll-Franse, L. van de; Oerlemans, S.; Bredart, A.; Kyriakou, C.; Sztankay, M.; Pallua, S.; Daniels, L.; Creutzberg, C.L.; Cocks, K.; Malak, S.; Caocci, G.; Molica, S.; Chie, W.C.; Efficace, F. & EORTC Quality Life Grp (2018), International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia, Quality of Life Research 27(2): 333-345.
- Boer, S.M. de; Wortman, B.G.; Bosse, T.; Powell, M.E.; Singh, N.; Hollema, H.; Wilson, G.; Chowdhury, M.N.; Mileshkin, L.; Pyman, J.; Katsaros, D.; Carinelli, S.; Fyles, A.; McLachlin, C.M.; Haie-Meder, C.; Duvillard, P.; Nout, R.A.; Verhoeven-Adema, K.W.; Putter, H.; Creutzberg, C.L.; Smit, V.T.H.B.M. & PORTEC Study Grp (2018), Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer., Annals of Oncology.
- Gool, I.C. van; Ubachs, J.E.H.; Stelloo, E.; Kroon, C.D. de; Goeman, J.J.; Smit, V.T.H.B.M.; Creutzberg, C.L. & Bosse, T. (2018), Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolf's clothing, Histopathology 72(2): 248-258.
- Boer, S.M. de; Nout, R.A.; Bosse, T. & Creutzberg, C.L. (2018), Adjuvant therapy for high-risk endometrial cancer: recent evidence and future directions., Expert Review of Anticancer Therapy.
- Eggink, F.A.; Gool, I.C. van; Leary, A.; Pollock, P.M.; Crosbie, E.J.; Mileshkin, L.; Jordanova, E.S.; Adam, J.; Freeman-Mills, L.; Church, D.N.; Creutzberg, C.L.; Bruyn, M. de; Nijman, H.W. & Bosse, T. (2017), Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition, OncoImmunology 6(2).
- Depreeuw, J.; Stelloo, E.; Osse, E.M.; Creutzberg, C.L.; Nout, R.A.; Moisse, M.; Garcia-Dios, D.A.; Dewaele, M.; Willekens, K.; Marine, J.C.; Matias-Guiu, X.; Amant, F.; Lambrechts, D. & Bosse, T. (2017), Amplification of 1q32.1 Refines the Molecular Classification of Endometrial Carcinoma, Clinical Cancer Research 23(23): 7232-7241.
- Eggink, F.A.; Mom, C.H.; Bouwman, K.; Boll, D.; Becker, J.H.; Creutzberg, C.L.; Niemeijer, G.C.; Driel, W.J. van; Reyners, A.K.; Zee, A.G. van der; Bremer, G.L.; Ezendam, N.P.; Kruitwagen, R.F.; Pijnenborg, J.M.; Hollema, H.; Nijman, H.W. & Aa, M.A. van der (2017), Less-favourable prognosis for low-risk endometrial cancer patients with a discordant pre- versus post-operative risk stratification (vol 78, pg 82, 2017), European Journal of Cancer 84: 370-370.
- Bakker, R.M.; Kenter, G.G.; Creutzberg, C.L.; Stiggelbout, A.M.; Derks, M.; Mingelen, W.; Kroon, C.D.; Vermeer, W.M. & Kuile, M.M. ter (2017), Sexual distress and associated factors among cervical cancer survivors: A cross-sectional multicenter observational study, Psycho-Oncology 26(10): 1470-1477.
- Querleu, D.; Planchamp, F.; Chiva, L.; Fotopoulou, C.; Barton, D.; Cibula, D.; Aletti, G.; Carinelli, S.; Creutzberg, C.; Davidson, B.; Harter, P.; Lundvall, L.; Marth, C.; Morice, P.; Rafii, A.; Ray-Coquard, I.; Rockall, A.; Sessa, C.; Zee, A. van der; Vergote, I. & duBois, A. (2017), European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery, International Journal of Gynecological Cancer 27(7): 1534-1542.
- Edmondson, R.J.; Crosbie, E.J.; Nickkho-Amiry, M.; Kaufmann, A.; Stelloo, E.; Nijman, H.W.; Leary, A.; Auguste, A.; Mileshkin, L.; Pollock, P.; MacKay, H.J.; Powell, M.E.; Bosse, T.; Creutzberg, C.L. & Kitchener, H.C. (2017), Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative, Gynecologic Oncology 146(2): 327-333.
- Colombo, N.; Creutzberg, C.; Querleu, D.; Barahona, M.; Sessa, C. & ESMO Guidelines Comm (2017), Appendix 5: Endometrial cancer: eUpdate published online 8 June 2017 (www.esmo.org/Guidelines/Gynaecological-Cancers), Annals of Oncology 28: 153-156.
- Bakker, R.M.; Pieterse, Q.D.; Lonkhuijzen, L.R.C.W. van; Trimbos, B.J.B.M.Z.; Creutzberg, C.L.; Kenter, G.G.; Kroon, C.D. de & Kuile, M.M. ter (2017), A Controlled Study on Vaginal Blood Flow During Sexual Arousal Among Early-Stage Cervical Cancer Survivors Treated With Conventional Radical or Nerve-Sparing Surgery With or Without Radiotherapy, International Journal of Gynecological Cancer 27(5): 1051-1057.
- Eggink, F.A.; Mom, C.H.; Bouwman, K.; Boll, D.; Becker, J.H.; Creutzberg, C.L.; Niemeijer, G.C.; Driel, W.J. van; Reyners, A.K.; Zee, A.G. van der; Bremer, G.L.; Ezendam, N.P.; Kruitwagen, R.F.; Pijnenborg, J.M.; Hollema, H.; Nijman, H.W. & Aa, M.A. van der (2017), Less-favourable prognosis for low-risk endometrial cancer patients with a discordant pre-versus post-operative risk stratification, European Journal of Cancer 78: 82-90.
- Wiltink, L.M.; Nout, R.A.; Fiocco, M.; Creutzberg, C.L. & Marijnen, C.A.M. (2017), Postoperative Pelvic Radiotherapy in Patients With Endometrial Cancer May Increase the Risk for Secondary Pelvic Cancers: A Post Hoc Analysis of Results From the TME, PORTEC-1, and PORTEC-2 Trials Reply, Journal of Clinical Oncology 35(16): 1862-+.
- Luyten, G.; Marinkovic, M.; Sommers, L.; Horeweg, N.; Fiocco, M.; Bleeker, J. & Creutzberg, C.L. (2017), Ruthenium-106 brachytherapy for uveal melanoma without transpupillary thermotherapy: similar efficacy with improved visual outcome, Acta Ophthalmologica 95: 15-15.
- Esterik, M. van; Gool, I.C. van; Kroon, C.D. de; Nout, R.A.; Creutzberg, C.L.; Smit, V.T.H.B.M.; Bosse, T. & Stelloo, E. (2017), Limited impact of intratumour heterogeneity on molecular risk assignment in endometrial cancer, Oncotarget 8(15): 25542-25551.
- Bakker, R.M.; Mens, J.W.M.; Groot, H.E. de; Tuijnman-Raasveld, C.C.; Braat, C.; Hompus, W.C.P.; Poelman, J.G.M.; Laman, M.S.; Velema, L.A.; Kroon, C.D. de; Doorn, H.C. van; Creutzberg, C.L. & Kuile, M.M. ter (2017), A nurse-led sexual rehabilitation intervention after radiotherapy for gynecological cancer, Supportive Care in Cancer 25(3): 729-737.
- Stelloo, E.; Jansen, A.M.L.; Osse, E.M.; Nout, R.A.; Creutzberg, C.L.; Ruano, D.; Church, D.N.; Morreau, H.; Smit, V.T.H.B.M.; Wezel, T. van & Bosse, T. (2017), Practical guidance for mismatch repair-deficiency testing in endometrial cancer, Annals of Oncology 28(1): 96-102.
- Marinkovic M., Horeweg N., Fiocco M., Peters F.P., Sommers L.W., Laman M.S., Bleeker J.C., Ketelaars M., Luyten G.P.M. & Creutzberg C.L. (2016), Ruthenium-106 brachytherapy for choroidal melanoma without transpupillary thermotherapy: Similar efficacy with improved visual outcome, European Journal of Cancer 68: 106-113.
- Marinkovic, M.; Horeweg, N.; Fiocco, M.; Peters, F.P.; Sommers, L.W.; Laman, M.S.; Bleeker, J.C.; Ketelaars, M.; Luyten, G.P.M. & Creutzberg, C.L. (2016), Ruthenium-106 brachytherapy for choroidal melanoma without transpupillary thermotherapy: Similar efficacy with improved visual outcome, European Journal of Cancer 68: 106-113.
- Blinman, P.; Mileshkin, L.; Khaw, P.; Goss, G.; Johnson, C.; Capp, A.; Brooks, S.; Wain, G.; Kolodziej, I.; Veillard, A.S.; O'Connell, R.; Creutzberg, C.L.; Stockler, M.R.; ANZGOG & PORTEC Grp (2016), Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial, British Journal of Cancer 115(10): 1179-1185.
- Bakker, R.; Mens, J.W.; Groot, E. de; Tuijnman-Raasveld, C.; Braat, C.; Hompus, W.; Poelman, J.; Laman, M.; Kroon, C. de; Doorn, L. van; Creutzberg, C. & Kuile, M. ter (2016), A sexual rehabilitation programme for gynaecological cancer patients after radiation therapy: Final results of a pilot-study, Psycho-Oncology 25(SP. S3): 185-185.
- Nooij, L.S.; Brand, F.A.M.; Gaarenstroom, K.N.; Creutzberg, C.L.; Hullu, J.A. de & Poelgeest, M.I.E. van (2016), Risk factors and treatment for recurrent vulvar squamous cell carcinoma, Critical Reviews in Oncology/Hematology 106: 1-13.
- Bakker, R.M.; Mens, J.W.M.; Groot, H.E. de; Tuijnman-Raasveld, C.C.; Braat, C.; Hompus, W.C.P.; Poelman, J.G.M.; Laman, M.S.; Velema, L.A.; Kroon, C.D. de; Doorn, H.C. van; Creutzberg, C.L. & Kuile, M.M. ter (2016), A nurse-led sexual rehabilitation intervention after radiotherapy for gynecological cancer, Supportive Care in Cancer.
- Stelloo, E.; Jansen, A.; Osse, E.; Nout, R.; Ruano, D.; Wezel, T. van; Creutzberg, C.; Smit, V.; Morreau, H. & Bosse, E. (2016), Comprehensive analysis of microsatellite instability and mismatch repair protein expression in nearly 700 endometrial cancers, Virchows Archiv 469: S19-S19.
- Querleu, D.; Planchamp, F.; Chiva, L.; Fotopoulou, C.; Barton, D.; Cibula, D.; Aletti, G.; Carinelli, S.; Creutzberg, C.; Davidson, B.; Harter, P.; Lundvall, L.; Marth, C.; Morice, P.; Rafii, A.; Ray-Coquard, I.; Rockall, A.; Sessa, C.; Zee, A. van der; Vergote, I. & Bois, A. du (2016), European Society of Gynaecologic Oncology Quality Indicators for Advanced Ovarian Cancer Surgery, International Journal of Gynecological Cancer 26(7): 1354-1363.
- Lutgens, L.C.H.W.; Koper, P.C.M.; Jobsen, J.J.; Steen-Banasik, E.M. van der; Creutzberg, C.L.; Berg, H.A. van den; Ottevanger, P.B.; Rhoon, G.C. van; Doorm, H.C. van; Houben, R. & Zee, J. van der (2016), Radiation therapy combined with hyperthermia versus cisplatin for locally advanced cervical cancer: Results of the randomized RADCHOC trial, Radiotherapy and Oncology 120(3): 378-382.
- Nooij, L.S.; Slot, M.A. van der; Dekkers, O.M.; Stijnen, T.; Gaarenstroom, K.N.; Creutzberg, C.L.; Smit, V.T.H.B.M.; Bosse, T. & Poelgeest, M.I.E. van (2016), Tumour-free margins in vulvar squamous cell carcinoma: Does distance really matter?, European Journal of Cancer 65: 139-149.
- Sande, M.A.E. van de; Creutzberg, C.L.; Water, S. van de; Sharfo, A.W. & Hoogeman, M.S. (2016), Which cervical and endometrial cancer patients will benefit most from intensity-modulated proton therapy?, Radiotherapy and Oncology 120(3): 397-403.
- Jameson, M.G.; McNamara, J.; Bailey, M.; Metcalfe, P.E.; Holloway, L.C.; Foo, K.; , V. do; Mileshkin, L.; Creutzberg, C.L. & Khaw, P. (2016), Results of the Australasian (Trans-Tasman Oncology Group) radiotherapy benchmarking exercise in preparation for participation in the PORTEC-3 trial, Journal of Medical Imaging and Radiation Oncology 60(4): 554-559.
- Boer, S.M. de; Powell, M.E.; Mileshkin, L.; Katsaros, D.; Bessette, P.; Haie-Meder, C.; Ottevanger, P.B.; Ledermann, J.A.; Khaw, P.; Colombo, A.; Fyles, A.; Baron, M.H.; Kitchener, H.C.; Nijman, H.W.; Kruitwagen, R.F.; Nout, R.A.; Verhoeven-Adema, K.W.; Smit, V.T.; Putter, H.; Creutzberg, C.L. & PORTEC Study Grp (2016), Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial, Lancet Oncology 17(8): 1114-1126.
- Stelloo, E.; Nout, R.A.; Osse, E.M.; Jurgenliemk-Schulz, I.J.; Jobsen, J.J.; Lutgens, L.C.; Steen-Banasik, E.M. van der; Nijman, H.W.; Putter, H.; Bosse, T.; Creutzberg, C.L. & Smit, V.T.H.B.M. (2016), Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts, Clinical Cancer Research 22(16): 4215-4224.
- Chuang, L.T.; Randall, T.C.; Denny, L.; Johnston, C.M.; Schmeler, K.M.; Covens, A.L.; Cibula, D.; Bookman, M.A.; Rawal, S.; DePetrillo, D.; Nam, J.H.; Goodman, A.; Naik, R.; Manchanda, R.; Gaffney, D.K.; Small, W.; Creutzberg, C.; Rattray, C.; Kesic, V.; Paraja, R.; Eiken, M.; Belleson, K.; Coleman, R.L.; Barakat, R.R.; Trimble, E.L. & Quinn, M. (2016), Sister Society Meeting on Global Education Development and Collaboration Meeting Report, International Journal of Gynecological Cancer 26(6): 1186-1188.
- Stelloo, E.; Versluis, M.A.; Nijman, H.W.; Bruyn, M. de; Plat, A.; Osse, E.M.; Dijk, R.H. van; Nout, R.A.; Creutzberg, C.L.; Bock, G.H. de; Smit, V.T.; Bosse, T. & Hollema, H. (2016), Microsatellite instability derived JAK1 frameshift mutations are associated with tumor immune evasion in endometrioid endometrial cancer, Oncotarget 7(26): 39885-39893.
- Morice, P.; Leary, A.; Creutzberg, C.; Abu-Rustum, N. & Darai, E. (2016), Endometrial cancer, Lancet 387(10023): 1094-1108.
- Creutzberg, C.L. (2016), Hyperbaric oxygen therapy for radiation-induced injury: evidence is needed, Lancet Oncology 17(2): 132-134.
- Gool, I.C. van; Stelloo, E.; Nout, R.A.; Nijman, H.W.; Edmondson, R.J.; Church, D.N.; MacKay, H.J.; Leary, A.; Powell, M.E.; Mileshkin, L.; Creutzberg, C.L.; Smit, V.T.H.B.M. & Bosse, T. (2016), Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer, Modern Pathology 29(2): 174-181.
- Colombo, N.; Creutzberg, C.; Amant, F.; Bosse, T.; Gonzalez-Martin, A.; Ledermann, J.; Marth, C.; Nout, R.; Querleu, D.; Mirza, M.R.; Sessa, C. & ESMO-ESGO-ESTRO Endometrial Consen (2016), ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up, Annals of Oncology 27(1): 16-41.
- Colombo, N.; Creutzberg, C.; Amant, F.; Bosse, T.; Gonzalez-Martin, A.; Ledermann, J.; Marth, C.; Nout, R.; Querleu, D.; Mirza, M.R.; Sessa, C. & ESMO-ESGO-ESTRO Endometrial Conse (2016), ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer Diagnosis, Treatment and Follow-up, International Journal of Gynecological Cancer 26(1): 2-30.
- Bakker, R.M.; Kenter, G.G.; Creutzberg, C.L.; Stiggelbout, A.M.; Derks, M.; Mingelen, W.; Kroon, C.D.; Vermeer, W.M. & Kuile, M.M. ter (2016), Sexual distress and associated factors among cervical cancer survivors, Psycho-Oncology.
- Chuang, L.T.; Randall, T.C.; Denny, L.; Johnston, C.M.; Schmeler, K.M.; Covens, A.L.; Cibula, D.; Bookman, M.A.; Rawal, S.; DePetrillo, D.; Nam, J.H.; Goodman, A.; Naik, R.; Manchanda, R.; Gaffney, D.K.; Small, W.; Creutzberg, C.; Rattray, C.; Kesic, V.; Paraja, R.; Eiken, M.; Belleson, K.; Coleman, R.L.; Barakat, R.R.; Trimble, E.L. & Quinn, M. (2016), Sister Society Meeting on Global Education Development and Collaboration: Meeting Report., International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
- Boer, S.M. de; Powell, M.E.; Mileshkin, L.; Katsaros, D.; Bessette, P.; Haie-Meder, C.; Ottevanger, P.B.; Ledermann, J.A.; Khaw, P.; Colombo, A.; Fyles, A.; Baron, M.H.; Kitchener, H.C.; Nijman, H.W.; Kruitwagen, R.F.; Nout, R.A.; Verhoeven-Adema, K.W.; Smit, V.T.; Putter, H.; Creutzberg, C.L. & PORTEC Study Grp (2016), Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial., The Lancet. Oncology.
- Colombo, N.; Creutzberg, C.; Amant, F.; Bosse, T.; Gonzalez-Martin, A.; Ledermann, J.; Marth, C.; Nout, R.; Querleu, D.; Mirza, M.R.; Sessa, C. & ESMO-ESGO-ESTRO Endometrial (2015), ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up, Radiotherapy and Oncology 117(3): 559-581.
- Nooij, L.S.; Ongkiehong, P.J.; Zwet, E.W. van; Bosse, T.; Creutzberg, C.L.; Gaarenstroom, K.N. & Poelgeest, M.I.E. van (2015), Groin surgery and risk of recurrence in lymph node positive patients with vulvar squamous cell carcinoma, Gynecologic Oncology 139(3): 458-464.
- Boer, S.M. de; Nout, R.A.; Jurgenliemk-Schulz, I.M.; Jobsen, J.J.; Lutgens, L.C.H.W.; Steen-Banasik, E.M. van der; Mens, J.W.M.; Slot, A.; Kroese, M.C.S.; Oerlemans, S.; Putter, H.; Verhoeven-Adema, K.W.; Nijman, H.W. & Creutzberg, C.L. (2015), Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship: Results From the Randomized PORTEC-2 Trial, International Journal of Radiation Oncology - Biology - Physics 93(4): 797-809.
- Linthorst, M.; Baaijens, M.; Wiggenraad, R.; Creutzberg, C.; Ghidey, W.; Rhoon, G.C. van & Zee, J. van der (2015), Local control rate after the combination of re-irradiation and hyperthermia for irresectable recurrent breast cancer: Results in 248 patients, Radiotherapy and Oncology 117(2): 217-222.
- Lim, K.; Erickson, B.; Juurgenliemk-Schulz, I.M.; Gaffney, D.; Creutzberg, C.L.; Viswanathan, A.; Portelance, L.; Beriwal, S.; Wolfson, A.; Bosch, W.; Santos, J.D.L.; Yashar, C.; Jhingran, A.; Varia, M.; Naqa, I. el; King, B. & Fyles, A. (2015), Variability in clinical target volume delineation for intensity modulated radiation therapy in 3 challenging cervix cancer scenarios, Practical Radiation Oncology 5(6): E557-E565.
- Bakker, R.; Mens, J.W.M.; Creutzberg, C.L.; Groot, H.E. de; Tuijnman-Raasveld, C.C.; Braat, C.; Hompus, W.C.P.; Poelman, J.G.M.; Laman, S.; Kroon, C.D. de; Doorn, H.C. van & Kuile, M.M. ter (2015), A PILOT-STUDY OF A SEXUAL REHABILITATION PROGRAMME FOR GYNECOLOGICAL CANCER PATIENTS AFTER PELVIC RADIATION THERAPY., International Journal of Gynecological Cancer 25(9): 608-608.
- Amant, F.; Mirza, M.R.; Koskas, M. & Creutzberg, C.L. (2015), Cancer of the corpus uteri, International Journal of Gynecology and Obstetrics 131: S96-S104.
- Nooij, L.S.; Ongkiehong, P.J.; Zwet, E.W. van; Bosse, T.; Creutzberg, C.L.; Gaarenstroom, K.N. & Poelgeest, M.I.E. van (2015), NODAL DEBULKING VERSUS FULL INGUINOFEMORAL LYMPHADENECTOMY AND RISK OF RECURRENCE IN LYMPH NODE POSITIVE VULVAR SQUAMOUS CELL CARCINOMA PATIENTS, International Journal of Gynecological Cancer 25(9): 680-680.
- Boer, S.M. de; Powell, M.E.; Mileshkin, L.; Katsaros, D.; Bessette, P.; Haie-Meder, C.; Nout, R.A.; Kitchener, H.C.; Ottevanger, P.B.; Khaw, P.; Colombo, A.; Fyles, A.; Baron, M.H.; Nijman, H.W.; Kruitwagen, R.; Ledermann, J.; Verhoeven-Adema, K.W.; Smit, V.T.; Putter, H. & Creutzberg, C.L. (2015), RELATION BETWEEN PATIENT AND PHYSICIAN REPORTED TOXICITY IN THE RANDOMISED PORTEC-3 TRIAL OF RADIATION THERAPY (RT) WITH OR WITHOUT CHEMOTHERAPY FOR ENDOMETRIAL CANCER, International Journal of Gynecological Cancer 25(9): 278-279.
- Kondalsamy-Chennakesavan, S.; Nasir, B.; Creutzberg, C.L.; Stiphout, R.G.P.M. van; Nout, R.A.; Lutgens, L.C.H.W.; Jurgenliemk-Schulz, M.; Lambin, P.; Kwan, M.M.S. & Obermair, A. (2015), VALIDATION OF THE AUSTRALIAN UTERINE CANCER NOMOGRAMS TO PREDICT LOCAL OR DISTANT RECURRENCE USING PORTEC TRIALS DATASET, International Journal of Gynecological Cancer 25(9): 289-290.
- Gool, I. van; Eggink, F.; Freeman-Mills, L.; Stelloo, E.; Marchi, E.; Palles, C.; Bruyn, M. de; Nout, R.; Kroon, C. de; Osse, M.; Klenerman, P.; Creutzberg, C.; Tomlinson, I.; Smit, V.; Nijman, H.; Bosse, T. & Church, D. (2015), POLE proofreading mutations elicit an anti-tumor immune response in endometrial cancer, European Journal of Cancer 51: S29-S29.
- Dogrusoz, M.; Kroes, W.G.M.; Duinen, S.G. van; Creutzberg, C.L.; Versluis, M.; Bleeker, J.C.; Marinkovic, M.; Luyten, G.P.M. & Jager, M.J. (2015), Radiation Treatment Affects Chromosome Testing in Uveal Melanoma, Investigative Ophthalmology & Visual Science 56(10): 5956-5964.
- Bosse, T.; Peters, E.E.M.; Creutzberg, C.L.; Jurenliemk-Schulz, I.M.; Jobsen, J.J.; Mens, J.W.M.; Lutgens, L.C.H.W.; Steen-Banasik, E.M. van der; Smit, V.T.H.B.M. & Nout, R.A. (2015), Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer - A pooled analysis of PORTEC 1 and 2 trials, European Journal of Cancer 51(13): 1742-1750.
- Versluis, M.A.; Jong, R.A. de; Plat, A.; Bosse, T.; Smit, V.T.; Mackay, H.; Powell, M.; Leary, A.; Mileshkin, L.; Kitchener, H.C.; Crosbie, E.J.; Edmondson, R.J.; Creutzberg, C.L.; Hollema, H.; Daemen, T.; Bock, G.H. de & Nijman, H.W. (2015), Prediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parameters, British Journal of Cancer 113(5): 786-793.
- Gool, I.C. van; Eggink, F.A.; Freeman-Mills, L.; Stelloo, E.; Marchi, E.; Bruyn, M. de; Palles, C.; Nout, R.A.; Kroon, C.D. de; Osse, E.M.; Klenerman, P.; Creutzberg, C.L.; Tomlinson, I.P.M.; Smit, V.T.H.B.M.; Nijman, H.W.; Bosse, T. & Church, D.N. (2015), POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer, Clinical Cancer Research 21(14): 3347-3355.
- Malak, S.; Oerlemans, S.; Efficace, F.; Bredart, A.; Kyriakou, C.; Daniels, L.; Creutzberg, C.; Cocks, K.; Sztankay, M.; Pallua, S.; Caocci, G.; Molica, S.; Chie, W. & Poll-Franse, L. van de (2015), CROSS-CULTURAL DEVELOPMENT OF FOUR EORTC QUESTIONNAIRES TO ASSESS QUALITY OF LIFE IN PATIENTS WITH HODGKIN LYMPHOMA, NON-HODGKIN LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKAEMIA, Haematologica 100: 149-149.
- Dogrusoz, M.; Kroes, W.G.M.; Duinen, S. van; Creutzberg, C.L.; Versluis, M.; Bleeker, J.C.; Marinkovic, M.; Luyten, G.P.M. & Jager, M.J. (2015), Irradiation enhances chromosomal aberrations in uveal melanoma, Investigative Ophthalmology & Visual Science 56(7).
- Stelloo, E.; Bosse, T.; Nout, R.A.; MacKay, H.J.; Church, D.N.; Nijman, H.W.; Leary, A.; Edmondson, R.J.; Powell, M.E.; Crosbie, E.J.; Kitchener, H.C.; Mileshkin, L.; Pollock, P.M.; Smit, V.T. & Creutzberg, C.L. (2015), Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative, Modern Pathology 28(6): 836-844.
- Mitra, D.; Nout, R.; Catalano, P.J.; Creutzberg, C.; Cimbak, N.; Lee, L. & Viswanathan, A.N. (2015), Rectal bleeding after radiation therapy for endometrial cancer, Radiotherapy and Oncology 115(2): 240-245.
- Creutzberg, C.L.; Boer, S.M. de; Putter, H.; Powell, M.; Mileshkin, L.R.; Katsaros, D.; Bessette, P.; Haie-Meder, C.; Ledermann, J.A.; Ottevanger, P.B.; Khaw, P.; Colombo, A.; Fyles, A.W.; Baron, M.H.; Nijman, H.W.; Nout, R.A.; Smit, V.T.H.B.M.; Verhoeven-Adema, K.; Kruitwagen, R.F.P.M. & Kitchener, H.C. (2015), Adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer: Toxicity and quality-of-life results of the randomized PORTEC-3 trial., Journal of Clinical Oncology 33(15).
- Wiltink, L.M.; Nout, R.A.; Fiocco, M.; Kranenbarg, E.M.K.; Jurgenliemk-Schulz, I.M.; Jobsen, J.J.; Nagtegaal, I.D.; Rutten, H.J.T.; Velde, C.J.H. van de; Creutzberg, C.L. & Marijnen, C.A.M. (2015), No Increased Risk of Second Cancer After Radiotherapy in Patients Treated for Rectal or Endometrial Cancer in the Randomized TME, PORTEC-1, and PORTEC-2 Trials, Journal of Clinical Oncology 33(15): 1640-+.
- Vermeer, W.M.; Bakker, R.M.; Stiggelbout, A.M.; Creutzberg, C.L.; Kenter, G.G. & Kuile, M.M. ter (2015), Psychosexual support for gynecological cancer survivors: professionals' current practices and need for assistance, Supportive Care in Cancer 23(3): 831-839.
- Bakker, R.M.; Vermeer, W.M.; Creutzberg, C.L.; Mens, J.W.M.; Nout, R.A. & Kuile, M.M. ter (2015), Qualitative Accounts of Patients' Determinants of Vaginal Dilator Use after Pelvic Radiotherapy, Journal of Sexual Medicine 12(3): 764-773.
- Creutzberg, C.L.; Stiphout, R.G.P.M. van; Nout, R.A.; Lutgens, L.C.H.W.; Jurgenliemk-Schulz, I.M.; Jobsen, J.J.; Smit, V.T.H.B.M. & Lambin, P. (2015), Nomograms for Prediction of Outcome With or Without Adjuvant Radiation Therapy for Patients With Endometrial Cancer: A Pooled Analysis of PORTEC-1 and PORTEC-2 Trials, International Journal of Radiation Oncology - Biology - Physics 91(3): 530-539.
- Church, D.N.; Stelloo, E.; Nout, R.A.; Valtcheva, N.; Depreeuw, J.; Haar, N. ter; Noske, A.; Amant, F.; Tomlinson, I.P.M.; Wild, P.J.; Lambrechts, D.; Jurgenliemk-Schulz, I.M.; Jobsen, J.J.; Smit, V.T.H.B.M.; Creutzberg, C.L. & Bosse, T. (2015), Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer, JNCI: Journal of the National Cancer Institute 107(1).
- Wiltink, L.M.; Nout, R.A.; Fiocco, M.; Kranenbarg, E.M.K.; Jurgenliemk-Schulz, I.M.; Jobsen, J.J.; Nagtegaal, I.D.; Rutten, H.J.T.; Velde, C.J.H. van de; Creutzberg, C.L. & Marijnen, C.A.M. (2015), No Increased Risk of Second Cancer After Radiotherapy in Patients Treated for Rectal or Endometrial Cancer in the Randomized TME, PORTEC-1, and PORTEC-2 Trials., Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
- Bakker, R.M.; Vermeer, W.M.; Creutzberg, C.L.; Mens, J.W.M.; Nout, R.A. & Kuile, M.M. ter (2015), Qualitative Accounts of Patients’ Determinants of Vaginal Dilator Use after Pelvic Radiotherapy, Journal of Sexual Medicine 12.
- Bosse, T.; Peters, E.E.M.; Creutzberg, C.L.; Jurenliemk-Schulz, I.M.; Jobsen, J.J.; Mens, J.W.M.; Lutgens, L.C.H.W.; Steen-Banasik, E.M. van der; Smit, V.T.H.B.M. & Nout, R.A. (2015), Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials., European journal of cancer (Oxford, England : 1990).
- Bosse, T.; Peters, E.E.M.; Creutzberg, C.L.; Jurenliemk-Schulz, I.M.; Jobsen, J.J.; Mens, J.W.M.; Lutgens, L.C.H.W.; Steen-Banasik, E.M. van der; Smit, V.T.H.B.M. & Nout, R.A. (2015), Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer, European Journal of Cancer 51(13).
- Genestie, C.; Adam, J.; Bosse, T.; Edmonson, R.; Kitchener, H.; Pollock, P.; Mileshkin, L.; Mackay, H.; Creutzberg, C. & Leary, A. (2014), EVALUATION OF DNA REPAIR BIOMARKERS IN HIGH-RISK ENDOMETRIAL CANCER: A TRANSPORTEC PILOT STUDY, International Journal of Gynecological Cancer 24(9): 1010-1011.
- Berton-Rigaud, D.; Devouassoux-Shisheboran, M.; Ledermann, J.A.; Leitao, M.M.; Powell, M.A.; Poveda, A.; Beale, P.; Glasspool, R.M.; Creutzberg, C.L.; Harter, P.; Kim, J.W.; Reed, N.S. & Ray-Coquard, I. (2014), Gynecologic Cancer InterGroup (GCIG) Consensus Review for Uterine and Ovarian Carcinosarcoma, International Journal of Gynecological Cancer 24(9): S55-S60.
- Sagae, S.; Susumu, N.; Viswanathan, A.N.; Aoki, D.; Backes, F.J.; Provencher, D.M.; Vaughan, M.; Creutzberg, C.L.; Kurzeder, C.; Kristensen, G.; Lee, C.; Kurtz, J.E.; Glasspool, R.M. & Small, W. (2014), Gynecologic Cancer InterGroup (GCIG) Consensus Review for Uterine Serous Carcinoma, International Journal of Gynecological Cancer 24(9): S83-S89.
- Rijkmans, E.C.; Nout, R.A.; Rutten, I.H.H.M.; Ketelaars, M.; Neelis, K.J.; Laman, M.S.; Coen, V.L.M.A.; Gaarenstroom, K.N.; Kroep, J.R. & Creutzberg, C.L. (2014), Improved survival of patients with cervical cancer treated with image-guided brachytherapy compared with conventional brachytherapy, Gynecologic Oncology 135(2): 231-238.
- Bosse, T.; Nout, R.A.; Stelloo, E.; Mackay, H.J.; Church, D.; Powell, M.; Leary, A.; Mileshkin, L.; Kitchener, H.; Smit, V. & Creutzberg, C.L. (2014), MOLECULAR PROFILING OF HIGH-RISK ENDOMETRIAL CANCER; A TRANSPORTEC PILOT STUDY, International Journal of Gynecological Cancer 24(9): 1503-1504.
- Blinman, P.; Mileshkin, L.; Khaw, P.; Goss, G.; Johnson, C.; Capp, A.; Brooks, S.; Wain, G.; Kolodzeij, I.; Veillard, A.S.; Creutzberg, C. & Stockler, M. (2014), PREFERENCES FOR ADJUVANT CHEMOTHERAPY IN AN ANZGOG SUBSTUDY OF THE PORTEC-3 INTERGROUP RANDOMIZED CONTROLLED TRIAL OF ADJUVANT CHEMOTHERAPY IN HIGH RISK ENDOMETRIAL CANCER.
- Church, D.; Stelloo, E.; Nout, R.A.; Valtcheva, N.; Depreeuw, J.; Haar, N. ter; Amant, F.; Tomlinson, I.P.M.; Wild, P.; Smit, V.; Creutzberg, C.L. & Bosse, T. (2014), PROGNOSTIC SIGNIFICANCE OF POLE EXONUCLEASE DOMAIN MUTATION IN EARLY STAGE ENDOMETRIAL CANCER, International Journal of Gynecological Cancer 24(9): 1601-1602.
- Nickkho-Amiry, M.; Kaufmann, A.; Bosse, T.; Leary, A.; McKay, H.; Powell, M.; Mileshkin, L.; Creutzberg, C.L.; Kitchener, H.C.; Crosbie, E.J. & Edmondson, R.J. (2014), USE OF MOLECULAR MARKERS IMPROVES PROGNOSTIC STRATIFICATION IN HIGH RISK ENDOMETRIAL CANCER: A TRANSPORTEC COLLABORATIVE STUDY, International Journal of Gynecological Cancer 24(9): 1501-1502.
- Bosse, T.; Nout, R.A.; Stelloo, E.; Dreef, E.; Nijman, H.W.; Jurgenliemk-Schulz, I.M.; Jobsen, J.J.; Creutzberg, C.L. & Smit, V.T.H.B.M. (2014), L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: Pooled PORTEC trial results, European Journal of Cancer 50(15): 2602-2610.
- Bakker, R.M.; Kuile, M.M. ter; Vermeer, W.M.; Nout, R.A.; Mens, J.W.M.; Doorn, L.C. van; Kroon, C.D. de; Hompus, W.C.P.; Braat, C. & Creutzberg, C.L. (2014), Sexual Rehabilitation After Pelvic Radiotherapy and Vaginal Dilator Use Consensus Using the Delphi Method, International Journal of Gynecological Cancer 24(8): 1499-1506.
- Vermeer, W.M.; Bakker, R.M.; Stiggelbout, A.M.; Creutzberg, C.L.; Kenter, G.G. & Kuile, M.M. ter (2014), Psychosexual support for gynecological cancer survivors: professionals' current practices and need for assistance., Supportive Care in Cancer.
- Wiltink L.M., Nout R.A., Fiocco M., Meershoek-Klein Kranenbarg E., Jurgenliemk-Schulz I.M., Jobsen J.J., Nagtegaal I.D., Velde C.J.H. van de, Creutzberg C.L. & Marijnen C.A.M. (2014), Second Cancers in Patients Treated With Surgery and Radiation Therapy for Rectal or Endometrial Cancer in the Randomized TME, PORTEC-1, and PORTEC-2 Trials, International Journal of Radiation Oncology - Biology - Physics 90(1): S85-S86.
- Small, W.; Bosch, W.R.; Strauss, J.B.; Albuquerque, K.; Beriwal, S.; Creutzberg, C.L.; Eifel, P.J.; Erickson, B.A.; Fyles, T.W.; Jhingran, A.; Klopp, A.H.; Kunos, C.; Mell, L.K.; Powell, M.; Viswanathan, A.N.; Yashar, C.M. & Gaffney, D. (2014), Consensus Guidelines for Delineation of Clinical Target Volume for Intensity-Modulated Pelvic Radiation Therapy in Postoperative Treatment of Endometrial and Cervical Cancer- An Update, International Journal of Radiation Oncology - Biology - Physics 90: S109-S109.
- Mitra, D.; Nout, R.; Creutzberg, C.; Lee, L.J.; Cimbak, N.C. & Viswanathan, A.N. (2014), Does Adding Vaginal Brachytherapy (VB) to External Beam (EB) Increase Rectal Bleeding?: Comparing Results of Combined EB plus VB to the PORTEC-2 Data for EB Alone and VB Alone, International Journal of Radiation Oncology - Biology - Physics 90: S710-S711.
- Daniels, L.A.; Krol, S.D.G.; Graaf, M.A. de; Scholte, A.J.H.A.; van't Veer, M.B.; Putter, H.; Roos, A. de; Schalij, M.J.; Poll-Franse, L.V. van de & Creutzberg, C.L. (2014), Impact of Cardiovascular Counseling and Screening in Hodgkin Lymphoma Survivors, International Journal of Radiation Oncology - Biology - Physics 90(1): 164-171.
- Nout, R.A.; Peters, E.E.M.; Jurgenlienik-Schulz, I.M.; Jobsen, J.J.; Mens, J.W.M.; Stelloo, E.; Smit, V.T.H.; Bosse, T. & Creutzberg, C.L. (2014), Quantification of LVSI Improves Its Strength as Prognostic Factor for Recurrence in Stage I Endometrial Cancer Patients Treated in the PORTEC Trials, International Journal of Radiation Oncology - Biology - Physics 90: S110-S111.
- Wiltink, L.M.; Nout, R.A.; Fiocco, M.; Kranenbarg, E.M.K.; Jurgenliemk-Schulz, I.M.; Jobsen, J.J.; Nagtegaal, I.D.; Velde, C.J.H. van de; Creutzberg, C.L. & Marijnen, C.A.M. (2014), Second Cancers in Patients Treated With Surgery and Radiation Therapy for Rectal or Endometrial Cancer in the Randomized TME, PORTEC-1, and PORTEC-2 Trials, International Journal of Radiation Oncology - Biology - Physics 90: S85-S86.
- Kunneman, M.; Pieterse, A.H.; Stiggelbout, A.M.; Nout, R.A.; Kamps, M.; Lutgens, L.C.H.W.; Paulissen, J.; Mattheussens, O.J.A.; Kruitwagen, R.F.P.M. & Creutzberg, C.L. (2014), Treatment preferences and involvement in treatment decision making of patients with endometrial cancer and clinicians, British Journal of Cancer 111(4): 674-679.
- Daniels, L.A.; Krol, A.D.G.; Graaf, M.A. de; Scholte, A.J.H.A.; van't Veer, M.B.; Putter, H.; Roos, A. de; Schalij, M.J. & Creutzberg, C.L. (2014), Screening for coronary artery disease after mediastinal irradiation in Hodgkin lymphoma survivors: phase II study of indication and acceptance, Annals of Oncology 25(6): 1198-1203.
- Arnold, M.; Liu, L.F.; Kenter, G.G.; Creutzberg, C.L.; Coebergh, J.W. & Soerjomataram, I. (2014), Second primary cancers in survivors of cervical cancer in the Netherlands: Implications for prevention and surveillance, Radiotherapy and Oncology 111(3): 374-381.
- Stelloo, E.; Nout, R.A.; Naves, L.C.L.M.; Haar, N.T. ter; Creutzberg, C.L.; Smit, V.T.H.B.M. & Bosse, T. (2014), High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma, Gynecologic Oncology 133(2): 197-204.
- Daniels, L.A.; Oerlemans, S.; Krol, A.D.G.; Creutzberg, C.L. & Poll-Franse, L.V. van de (2014), Chronic fatigue in Hodgkin lymphoma survivors and associations with anxiety, depression and comorbidity, British Journal of Cancer 110(4): 868-874.
- LR S, van der Kaaij M, van Dorst E, C C, E H & CE K (2014), Sexual dysfunction and infertility as late effects of cancer treatment., EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.].
- Bakker, R.M.; Kuile, M.M. ter; Vermeer, W.M.; Nout, R.A.; Mens, J.W.M.; Doorn, L.C. van; Kroon, C.D. de; Hompus, W.C.P.; Braat, C. & Creutzberg, C.L. (2014), Sexual Rehabilitation After Pelvic Radiotherapy and Vaginal Dilator Use Consensus Using the Delphi Method, International Journal of Gynecological Cancer 24(8).
- Bakker, R.M.; Kuile, M.M. ter; Vermeer, W.M.; Nout, R.A.; Mens, J.W.M.; Doorn, L.C. van; Kroon, C.D. de; Hompus, W.C.P.; Braat, C. & Creutzberg, C.L. (2014), Sexual rehabilitation after pelvic radiotherapy and vaginal dilator use: consensus using the Delphi method., International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
- Bosse, T.; Haar, N.T. ter; Seeber, L.M.; Diest, P.J. van; Hes, F.J.; Vasen, H.F.A.; Nout, R.A.; Creutzberg, C.L.; Morreau, H. & Smit, V.T.H.B.M. (2013), Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer, Modern Pathology 26(11): 1525-1535.
- Pieterse, Q.D.; Kenter, G.G.; Maas, C.P.; Kroon, C.D. de; Creutzberg, C.L.; Trimbos, J.B.M.Z. & Kuile, M.M. ter (2013), Self-Reported Sexual, Bowel and Bladder Function in Cervical Cancer Patients Following Different Treatment Modalities Longitudinal Prospective Cohort Study, International Journal of Gynecological Cancer 23(9): 1717-1725.
- Creutzberg, C.L.; Kitchener, H.C.; Birrer, M.J.; Landoni, F.; Lu, K.H.; Powell, M.; Aghajanian, C.; Edmondson, R.; Goodfellow, P.J.; Quinn, M.; Salvesen, H.B.; Thomas, G. & Second GCIG Endometrial Canc (2013), Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting Taking Endometrial Cancer Trials Into the Translational Era, International Journal of Gynecological Cancer 23(8): 1528-1534.
- Stelloo, E.; Nout, R.A.; Naves, L.C.L.M.; Haar, N.T. ter; Creutzberg, C.L.; Smit, T.H.B.M. & Bosse, T. (2013), HIGH CORRELATION OF MOLECULAR TUMOR ALTERATIONS IN ENDOMETRIAL CURRETAGE AND HYSTERECTOMY-SPECIMENS IN PATIENTS WITH ENDOMETRIAL CARCINOMA, International Journal of Gynecological Cancer 23(8).
- Daniels, L.A.; Krol, A.D.G.; Schaapveld, M.; Putter, H.; Jansen, P.M.; Marijt, E.W.A.; Leeuwen, F.E. van & Creutzberg, C.L. (2013), Long-term risk of secondary skin cancers after radiation therapy for Hodgkin's lymphoma, Radiotherapy and Oncology 109(1): 140-145.
- Creutzberg, C.L.; Stiphout, R.G.P.M. van; Nout, R.A.; Lutgens, L.C.H.W.; Jurgenliemk-Schulz, I.M.; Jobsen, J.J.; Smit, V.T.H. & Lambin, P. (2013), Nomogram for prediction of outcome for patients with endometrium cancer: a pooled analysis of PORTEC-1 and PORTEC-2 trials, European Journal of Cancer 49: S726-S727.
- Nout, R.; Boer, S. de; Putter, H.; Jurgenliemk-Schulz, I.; Jobsen, J.; Lutgens, L.; Steen-Banasik, E. van der; Mens, J.W.; Slot, A.; Stenfert-Kroese, M.; Verhoeven-Adema, K.; Stelloo, E.; Bosse, T.; Smit, V. & Creutzberg, C. (2013), Vaginal brachytherapy versus external beam pelvic radiotherapy for high-intermediate risk endometrial cancer: Long term results of the randomized PORTEC-2 trial, European Journal of Cancer 49: S714-S714.
- Creutzberg C.L. (13 september 2013). Over leven, lijden en leiden. Medicine, Leiden. Leiden. [oratie].
- Daniels, L.A.; Oerlemans, S.; Krol, A.D.G.; Poll-Franse, L.V. van de & Creutzberg, C.L. (2013), Persisting fatigue in Hodgkin lymphoma survivors: a systematic review, Annals of Hematology 92(8): 1023-1032.
- Felderhof, J.M.; Creutzberg, C.L.; Putter, H.; Nout, R.A.; Bovee, J.V.M.G.; Dijkstra, P.D.S.; Hartgrink, H.H. & Marijnen, C.A.M. (2013), Long-term clinical outcome of patients with soft tissue sarcomas treated with limb-sparing surgery and postoperative radiotherapy, Acta Oncologica 52(4): 745-752.
- Daniels, L.A.; Krol, A.; Graaf, M.A. de; Scholte, A.J.H.A.; Putter, H.; Veer, M.B.V.T.; Roos, A. de; Schalij, M.J. & Creutzberg, C.L. (2013), Screening for coronary artery disease after mediastinal irradiation in Hodgkin lymphoma survivors, Journal of Clinical Oncology 31(15).
- Creutzberg, C.L.; Kitchener, H.C.; Birrer, M.J.; Landoni, F.; Lu, K.H.; Powell, M.; Aghajanian, C.; Edmondson, R.; Goodfellow, P.J.; Quinn, M.; Salvesen, H.B.; Thomas, G. & Second GCIG Endometrial Canc (2013), Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting: taking endometrial cancer trials into the translational era., International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
- Pieterse, Q.D.; Kenter, G.G.; Maas, C.P.; Kroon, C.D. de; Creutzberg, C.L.; Trimbos, J.B.M.Z. & Kuile, M.M. ter (2013), Self-reported sexual, bowel and bladder function in cervical cancer patients following different treatment modalities: longitudinal prospective cohort study., International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
- Pieterse, Q.; Kenter, G.; Kroon, C. de; Creutzberg, C.; Trimbos, B. & Kuile, M. ter (2012), BLADDER, ANORECTAL AND SEXUAL FUNCTION AFTER NERVE-SPARING RADICAL HYSTERECTOMY FOR THE TREATMENT OF CERVICAL CANCER; A LONGITUDINAL PROSPECTIVE COHORT STUDY.
- Amant, F.; Mirza, M.R. & Creutzberg, C.L. (2012), Cancer of the corpus uteri, International Journal of Gynecology and Obstetrics 119: S110-S117.
- Oerlemans, S.; Husson, O.; Mols, F.; Poortmans, P.; Roerdink, H.; Daniels, L.A.; Creutzberg, C.L. & Poll-Franse, L.V. van de (2012), Perceived information provision and satisfaction among lymphoma and multiple myeloma survivors-results from a Dutch population-based study, Annals of Hematology 91(10): 1587-1595.
- Nout, R.A.; Bosse, T.; Creutzberg, C.L.; Jurgenliemk-Schulz, I.M.; Jobsen, J.J.; Lutgens, L.C.H.W.; Steen-Banasik, E.M. van der; Eijk, R. van; Haar, N.T. ter & Smit, V.T.H.B.M. (2012), Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/beta-catenin and P53 pathway activation, Gynecologic Oncology 126(3): 466-473.
- Nout, R.A.; Bosse, T.; Creutzberg, C.L.; Jurgenliemk-Schulz, I.M.; Jobsen, J.J.; Lutgens, L.C.H.W.; Steen-Banasik, E.M. van der; Eijk, R. van; Haar, N.T. ter & Smit, V.T.H.B.M. (2012), Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/β-catenin and P53 pathway activation., Gynecologic Oncology 126(3): 466-73.
- Nout, R.A.; Putter, H.; Jurgenliemk-Schulz, I.M.; Jobsen, J.J.; Lutgens, L.C.H.W.; Steen-Banasik, E.M. van der; Mens, J.W.M.; Slot, A.; Kroese, M.C.S.; Nijman, H.W.; Poll-Franse, L.V. van de & Creutzberg, C.L. (2012), Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data, European Journal of Cancer 48(11): 1638-1648.
- Razzaq, L.; Keunen, J.E.E.; Schalij-Delfos, N.E.; Creutzberg, C.L.; Ketelaars, M. & Keizer, R.J.W. de (2012), Ruthenium plaque radiation therapy for iris and iridociliary melanomas.
- Viswanathan, A.N.; Creutzberg, C.L.; Craighead, P.; McCormack, M.; Toita, T.; Narayan, K.; Reed, N.; Long, H.; Kim, H.J.; Marth, C.; Lindegaard, J.C.; Cerrotta, A.; Small, W. & Trimble, E. (2012), INTERNATIONAL BRACHYTHERAPY PRACTICE PATTERNS: A SURVEY OF THE GYNECOLOGIC CANCER INTERGROUP (GCIG), International Journal of Radiation Oncology - Biology - Physics 82(1): 250-255.
- Nout, R.A.; Bosse, T.; Creutzberg, C.L.; Jurgenliemk-Schulz, I.M.; Jobsen, J.J.; Lutgens, L.C.H.W.; Steen-Banasik, E.M. van der; Eijk, R. van; Haar, N.T. ter & Smit, V.T.H.B.M. (2012), Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/β-catenin and P53 pathway activation., Gynecologic Oncology.
- Oerlemans, S.; Husson, O.; Mols, F.; Poortmans, P.; Roerdink, H.; Daniels, L.A.; Creutzberg, C.L. & Poll-Franse, L.V. van de (2012), Perceived information provision and satisfaction among lymphoma and multiple myeloma survivors--results from a Dutch population-based study., Annals of Hematology.
- Creutzberg, C.L. & Nout, R.A. (2011), The Role of Radiotherapy in Endometrial Cancer: Current Evidence and Trends, Current Oncology Reports 13(6): 472-478.
- Nout, R.A.; Putter, H.; Jurgenliemk-Schulz, I.M.; Jobsen, J.J.; Lutgens, L.C.H.W.; Steen-Banasik, E.M. van der; Mens, J.W.M.; Slot, A.; Kroese, M.C.S.; Nijman, H.W.; Poll-Franse, L.V. van de & Creutzberg, C.L. (2011), Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data.
- Creutzberg, C.L.; Nout, R.A.; Lybeert, M.L.M.; Warlam-Rodenhuis, C.C.; Jobsen, J.J.; Mens, J.W.M.; Lutgens, L.C.H.W.; Pras, E.; Poll-Franse, L.V. van de; Putten, W.L.J. van & PORTEC Study Grp (2011), Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma., International Journal of Radiation Oncology - Biology - Physics 81(4): e631-8.
- Creutzberg, C.L.; Nout, R.A.; Lybeert, M.L.M.; Warlam-Rodenhuis, C.C.; Jobsen, J.J.; Mens, J.W.M.; Lutgens, L.C.H.W.; Pras, E.; Poll-Franse, L.V. van de; Putten, W.L.J. van & PORTEC Study Grp (2011), FIFTEEN-YEAR RADIOTHERAPY OUTCOMES OF THE RANDOMIZED PORTEC-1 TRIAL FOR ENDOMETRIAL CARCINOMA, International Journal of Radiation Oncology - Biology - Physics 81(4): E631-E638.
- Felderhof, J.M.; Creutzberg, C.L.; Putter, H.; Nout, R.A.; Bovee, J.V.M.G.; Dijkstra, P.D.S.; Harlgrink, H.H. & Marijnen, C.A.M. (2011), Limb-sparing Surgery and Radiotherapy for Soft Tissue Sarcomas of the Extremities, European Journal of Cancer 47: S667-S667.
- Coremans, I.; Wiggenraad, R.; Jong, M. de; Santvoort, J. van; Ages, D.; Putter, H.; Duinen, S. van; Natte, R.; Taphoorn, M.; Marijnen, C. & Creutzberg, C. (2011), PATTERNS OF RECURRENCE AND SURVIVAL IN 168 GLIOBLASTOMA PATIENTS AFTER TEMOZOLOMIDE BASED CHEMORADIATION, Radiotherapy and Oncology 99: S366-S367.
- Nout, R.A.; Poll-Franse, L.V. van de; Lybeert, M.L.M.; Warlam-Rodenhuis, C.C.; Jobsen, J.J.; Mens, J.W.M.; Lutgens, L.C.H.W.; Pras, B.; Putten, W.L.J. van & Creutzberg, C.L. (2011), Long-Term Outcome and Quality of Life of Patients With Endometrial Carcinoma Treated With or Without Pelvic Radiotherapy in the Post Operative Radiation Therapy in Endometrial Carcinoma 1 (PORTEC-1) Trial, Journal of Clinical Oncology 29(13): 1692-1700.
- Lim, K.; Small, W.; Portelance, L.; Creutzberg, C.; Jurgenliemk-Schulz, I.M.; Mundt, A.; Mell, L.K.; Mayr, N.; Viswanathan, A.; Jhingran, A.; Erickson, B.; Santos, J. de los; Gaffney, D.; Yashar, C.; Beriwal, S.; Wolfson, A.; Taylor, A.; Bosch, W.; Naqa, I. el; Fyles, A. & Gyn IMRT Consortium (2011), CONSENSUS GUIDELINES FOR DELINEATION OF CLINICAL TARGET VOLUME FOR INTENSITY-MODULATED PELVIC RADIOTHERAPY FOR THE DEFINITIVE TREATMENT OF CERVIX CANCER, International Journal of Radiation Oncology - Biology - Physics 79(2): 348-355.
- Greimel, E.; Nordin, A.; Lanceley, A.; Creutzberg, C.L.; Poll-Franse, L.V. van de; Radisic, V.B.; Galalae, R.; Schmalz, C.; Barlow, E.; Jensen, P.T.; Waldenstrom, A.C.; Bergmark, K.; Chie, W.C.; Kuljanic, K.; Costantini, A.; Singer, S.; Koensgen, D.; Menon, U.; Daghofer, F. & EORTC Quality Life Grp (2011), Psychometric validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer Module (EORTC QLQ-EN24), European Journal of Cancer 47(2): 183-190.
- Lim, K.; Fyles, A.; Portelance, L.; Creutzberg, C.; Jurgenliemk-Schulz, I.M.; Viswanathan, A.; Erickson, B.; Bosch, W.; Naqa, I. el & Varia, M. (2010), Variability in Clinical Target Volume Delineation for Intensity Modulated Radiotherapy in Three Challenging Cervix Cancer Scenarios, International Journal of Radiation Oncology - Biology - Physics 78(3): S121-S122.
- Poll-Franse, L.V. van de; Mols, F.; Gundy, C.M.; Creutzberg, C.L.; Nout, R.A.; Verdonck-de Leeuw, I.M.; Taphoorn, M.J. & Aaronson, N.K. (2010), Normative data for the EORTC QLQ-C30 and EORTC-sexuality items in the general Dutch population.
- Creutzberg, C.L. (2010), Adjuvant chemotherapy for endometrial cancer: unproven., International Journal of Gynecological Cancer 20(11 Suppl 2): S60-3.
- Creutzberg, C.L. (2010), Adjuvant Chemotherapy for Endometrial Cancer Unproven, International Journal of Gynecological Cancer 20: S60S63.
- Creutzberg, C.L. (2010), Adjuvant Chemotherapy for Endometrial Cancer Unproven, International Journal of Gynecological Cancer 20(7): 1105-1108.
- Razzaq, L.; Keunen, J.E.E.; Schalij-Delfos, N.E.; Creutzberg, C.L.; Ketelaars, M. & Keizer, R.J.W. de (2010), Ruthenium plaque radiation therapy for iris and iridociliary melanomas.
- Verschueren, K.M.S.; Creutzberg, C.L.; Schalij-Delfos, N.E.; Ketelaars, M.; Klijsen, F.L.L.; Haeseker, B.I.; Ligtenberg, S.M.B.; Keunen, J.E.E. & Marijnen, C.A.M. (2010), Long-term outcomes of eye-conserving treatment with Ruthenium(106) brachytherapy for choroidal melanoma, Radiotherapy and Oncology 95(3): 332-338.
- Hezewijk, M. van; Creutzberg, C.L.; Putter, H.; Chin, A.; Schneider, I.; Hoogeveen, M.; Willemze, R. & Marijnen, C.A.M. (2010), Efficacy of a hypofractionated schedule in electron beam radiotherapy for epithelial skin cancer: Analysis of 434 cases, Radiotherapy and Oncology 95(2): 245-249.
- Vergote, I.; Pujade-Lauraine, E.; Pignata, S.; Kristensen, G.B.; Ledermann, J.; Casado, A.; Sehouli, J.; Mirza, M.; Fossati, R.; Marth, C.; Creutzberg, C.; Campo, J. del; Siddiqui, N.; Calvert, P.; Bamias, A.; Tulunay, G.; Zee, A.G.J. van der; Bois, A. du & European Network Gynaecological (2010), European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Pharmaceutical Companies, International Journal of Gynecological Cancer 20(3): 476-478.
- Nout, R.A.; Smit, V.T.H.B.M.; Putter, H.; Juergenliemk-Schulz, I.M.; Jobsen, J.J.; Lutgens, L.C.H.W.; Steen-Banasik, E.M. van der; Mens, J.W.M.; Slot, A.; Kroese, M.C.S.; Bunningen, B.N.F.M. van; Ansink, A.C.; Putten, W.L.J. van; Creutzberg, C.L. & PORTEC Study Grp (2010), Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial, Lancet 375(9717): 816-823.
- Nout, R.A.; Smit, V.T.H.B.M.; Putter, H.; Juergenliemk-Schulz, I.M.; Jobsen, J.J.; Lutgens, L.C.H.W.; Steen-Banasik, E.M. van der; Mens, J.W.M.; Slot, A.; Kroese, M.C.S.; Bunningen, B.N.F.M. van; Ansink, A.C.; Putten, W.L.J. van; Creutzberg, C.L. & PORTEC Study Grp (2010), Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial., Lancet (London, England).
- Creutzberg CL, Nout RA, van de Poll-Franse VL, Lybeert MLM, Warlam-Rodenhuis CC, Jobsen JJ, Mens JWM, Lutgens LCHW, Pras E & van Putten WLJ (2009), Long-term Outcome of the Randomized PORTEC-1 Trial and Quality of Life of the Endometrial Cancer Survivors, International Journal of Radiation Oncology - Biology - Physics 75(3): S146S147.
- Nout RA, Smit VTHB, Putter H, Jurgenliemk-Schulz IM, Jobsen JJ, Lutgens LCHW, van der Steen-Banasik EM, Mens JM, Slot A & Creutzberg CL (2009), Vaginal Brachytherapy vs. External Beam Radiotherapy for High-intermediate Risk Endometrial Cancer: Results of the Randomized PORTEC-2 Trial after Central Pathology Review, International Journal of Radiation Oncology - Biology - Physics 75(3): S87S87.
- Fyles AW, Lim K, Small W, Portelance L, Gaffney D, Erickson B, de los Santos J, Ishikura S, Creutzberg C & Bosch W (2009), Variability in Delineation of Clinical Target Volumes for Cervix Cancer Intensity-modulated Pelvic Radiotherapy, International Journal of Radiation Oncology - Biology - Physics 75(3): S83S84.
- Nout RA, Putter H, Jurgenliemk-Schulz IM, Jobsen JJ, Lutgens LCHW, van der Steen-Banasik EM, Mens JWM, Slot A, Kroese MCS & van Bunningen BNFM (2009), Quality of Life After Pelvic Radiotherapy or Vaginal Brachytherapy for Endometrial Cancer: First Results of the Randomized PORTEC-2 Trial, Journal of Clinical Oncology 27(21): 3547-3556.
- Nout RA, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Mens JW, Slot A, Stenfert Kroese MC, van Bunningen BN, Smit VT, Nijman HW, van den Tol PP & Creutzberg CL (2009), Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial., Journal of Clinical Oncology 27(21): 3547-56.
- Kitchener, H.C.; Trimble, E.L. & Endometrial Canc Working Grp Gynec (2009), Endometrial cancer state of the science meeting., International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
- Franckena M, Lutgens LC, Koper PC, Kleynen CE, van der Steen-Banasik EM, Jobsen JJ, Leer JW, Creutzberg CL, Dielwart MF & van Norden Y (2009), RADIOTHERAPY AND HYPERTHERMIA FOR TREATMENT OF PRIMARY LOCALLY ADVANCED CERVIX CANCER: RESULTS IN 378 PATIENTS, International Journal of Radiation Oncology - Biology - Physics 73(1): 242-250.
- Small W, Mell LK, Anderson P, Creutzberg C, De Los Santos J, Gaffney D, Jhingran A, Portelance L, Schefter T, Iyer R, Varia M, Winter K & Mundt AJ (2008), Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer, International Journal of Radiation Oncology - Biology - Physics 71(2).
- Kleijn WC, Ogoshi K, Yamaoka K, Shigehisa T, Takeda Y, Creutzberg CL, Nortier JWR & Kaptein AA (2006), Conceptual equivalence and health-related quality of life: an exploratory study in Japanese and Dutch cancer patients, Quality of Life Research 15(6).
- Kleijn WC, Ogoshi K, Yamaoka K, Shigehisa T, Takeda Y, Creutzberg CL, Nortier JW & Kaptein AA (2006), Conceptual equivalence and health-related quality of life: an exploratory study in Japanese and Dutch cancer patients., Quality of Life Research 15(6): 1091-101.
- Scholten AN, Aliredjo R, Creutzberg CL & Smit VTHBM (2006), Combined E-cadherin, alpha-catenin, and beta-catenin expression is a favorable prognostic factor in endometrial carcinoma, International Journal of Gynecological Cancer 16(3).
- Scholten AN, Aliredjo R, Creutzberg CL & Smit VT (2006), Combined E-cadherin, alpha-catenin, and beta-catenin expression is a favorable prognostic factor in endometrial carcinoma., International Journal of Gynecological Cancer 16(3): 1379-85.
- Pieterse QD, Trimbos JB, Dijkman A, Creutzberg CL, Gaarenstroom KN, Peters AA & Kenter GG (2006), Postoperative radiation therapy improves prognosis in patients with adverse risk factors in localized, early-stage cervical cancer: a retrospective comparative study., International Journal of Gynecological Cancer 16(3): 1112-8.
- Pieterse QD, Trimbos JBMZ, Dijkman A, Creutzberg CL, Gaarenstroom KN, Peters AAW & Kenter GG (2006), Postoperative radiation therapy improves prognosis in patients with adverse risk factors in localized, early-stage cervical cancer: a retrospective comparative study, International Journal of Gynecological Cancer 16(3).
- Scholten, A.N.; Aliredjo, R.; Creutzberg, C.L. & Smit, V.T.H.B.M. (2006), Combined E-cadherin, alpha-catenin, and beta-catenin expression is a favorable prognostic factor in endometrial carcinoma., International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
- Scholten AN, van Putten WL, Beerman H, Smit VT, Koper PC, Lybeert ML, Jobsen JJ, Wárlám-Rodenhuis CC, De Winter KA, Lutgens LC, van Lent M, Creutzberg CL & (2005), Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review., International Journal of Radiation Oncology - Biology - Physics 63(3): 834-8.
- Scholten AN, van Putten WLJ, Beerman H, Smit VTHBM, Koper PCM, Lybeert MLM, Jobsen JJ, Warlam-Rodenhuis CC, De Winter KAJ, Lutgens LCHW, van Lent M & Creutzberg CL (2005), Postoperative radiotherapy for stage 1 endometrial carcinoma: Long-term outcome of the randomized PORTEC trial with central pathology review, International Journal of Radiation Oncology - Biology - Physics 63(3).
- Seynaeve C, Verhoog LC, van de Bosch LMC, van Geel AN, Menke-Pluymers M, Meijers-Heijboer EJ, van den Ouweland AMW, Wagner A, Creutzberg CL, Niermeijer MF, Klijn JGM & Brekelmans CTM (2004), Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy, European Journal of Cancer 40(8).
- Creutzberg CL, van Putten WLJ, Warlam-Rodenhuis CC, van den Bergh ACM, De Winter KAJ, Koper PCM, Lybeert MLM, Slot A, Lutgens LCHW, Kroese MCS, Beerman H & van Lent M (2004), Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: The postoperative radiation therapy in endometrial carcinoma trial, Journal of Clinical Oncology 22(7).
- Scholten AN, Smit VT, Beerman H, van Putten WL & Creutzberg CL (2004), Prognostic significance and interobserver variability of histologic grading systems for endometrial carcinoma., Cancer 100(4): 764-72.
- Scholten AN, Smit VTHBM, Beerman H, van Putten WLJ & Creutzberg CL (2004), Prognostic significance and interobserver variability of histologic grading systems for endometrial carcinoma, Cancer 100(4).
- Creutzberg CL (2004), Survival after relapse in patients with endometrial cancer: results from a randomized trial - Response to the letter to the editor by Pijnenborg et al., Gynecologic Oncology 92(1).
- Scholten AN, Creutzberg CL, van den Broek LJCM, Noordijk EM & Smit VTHBM (2003), Nuclear beta-catenin is a molecular feature of type 1 endometrial carcinoma, Journal of Pathology 201(3).
- Scholten AN, Creutzberg CL, van den Broek LJ, Noordijk EM & Smit VT (2003), Nuclear beta-catenin is a molecular feature of type I endometrial carcinoma., Journal of Pathology 201(3): 460-5.
- Creutzberg CL, van Putten WLJ, Koper PC, Lybeert MLM, Jobsen JJ, Warlam-Rodenhuis CC, De Winter KAJ, Lutgens LCHW, van den Bergh ACM, van der Steen-Banasik E, Beerman H & van Lent M (2003), Survival after relapse in patients with endometrial cancer: results from a randomized trial, Gynecologic Oncology 89(2).
- Scholten AN, Creutzberg CL, Noordijk EM & Smit VTHBM (2002), Long-term outcome in endometrial carcinoma favors a two- instead of a three-tiered grading system, International Journal of Radiation Oncology - Biology - Physics 52(4).
- Scholten AN, Creutzberg CL, Noordijk EM & Smit VT (2002), Long-term outcome in endometrial carcinoma favors a two- instead of a three-tiered grading system., International Journal of Radiation Oncology - Biology - Physics 52(4): 1067-74.
- Noordijk EM & Creutzberg CL (2002), [Is there an indication for additional local irradiation in conserving treatment of breast cancer patients aged 60 and over?], Nederlands Tijdschrift voor Geneeskunde 146(9): 395-8.
- de Boer HCJ, de Koste JRV, Creutzberg CL, Visser AG, Levendag PC & Heijmen BJM (2001), Electronic portal image assisted reduction of systematic set-up errors in head and neck irradiation, Radiotherapy and Oncology 61(3).
- Creutzberg CL, van Putten WLJ, Koper PC, Lybeert MLM, Jobsen JJ, Warlam-Rodenhuis CC, De Winter KAJ, Lutgens LCHW, van den Bergh ACM, van der Steen-Banasik E, Beerman H & van Lent M (2001), The morbidity of treatment for patients with stage I endometrial cancer: Results from a randomized trial, International Journal of Radiation Oncology - Biology - Physics 51(5).
- Olofsen-Van Acht, M.; Berg, H. van den; Quint, S.; Boer, H. de; Seven, M.; Koste, J.V. de; Creutzberg, C. & Visser, A. (2001), Reduction of irradiated small bowel volume and accurate patient positioning by use of a bellyboard device in pelvic radiotherapy of gynecological cancer patients, Radiotherapy and Oncology 59(1): 87-93.
- Essers M, Eggen M, Binnekamp D, Creutzberg CL & Heijmen BJM (2000), Chest wall irradiation with MLC-shaped photon and electron fields, International Journal of Radiation Oncology - Biology - Physics 48(4).
- Creutzberg, C. & Putten, W. van (2000), Treatment for patients with stage-1 endometrial carcinoma - Reply.
- Creutzberg, C.L.; Putten, W.L.J. van; Koper, P.C.M.; Lybeert, M.L.M.; Jobsen, J.J.; Warlam-Rodenhuis, C.C.; Winter, K.A.J. de; Lutgens, L.C.H.W.; Bergh, A.C.M. van den; Steen-Banasik, E. van de; Beerman, H.; Lent, M. van & PORTEC Study Grp (2000), Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial, The Lancet 355(9213): 1404-1411.
- Creutzberg, C.L.; Putten, W.L.J. van; Koper, P.C.M.; Lybeert, M.L.M.; Jobsen, J.J.; Warlam-Rodenhuis, C.C.; Winter, K.A.J. de; Lutgens, L.C.H.W.; Bergh, A.C.M. van den; Steen-Banasik, E. van de; Beerman, H.; Lent, M. van & PORTEC Study Grp (2000), Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma., Lancet (London, England).
- Bel, A.; Vos, P.H.; Rodrigus, P.T.R.; Creutzberg, C.L.; Visser, A.G.; Stroom, J.C. & Lebesque, J.V. (1996), High-precision prostate cancer irradiation by clinical application of an offline patient setup verification procedure, using portal imaging, International Journal of Radiation Oncology - Biology - Physics 35(2): 321-332.
- Creutzberg, C.L.; Althof, V.G.M.; deHoog, M.; Visser, A.G.; Huizenga, H.; Wijnmaalen, A. & Levendag, P.C. (1996), A quality control study of the accuracy of patient positioning in irradiation of pelvic fields, International Journal of Radiation Oncology - Biology - Physics 34(3): 697-708.
- CREUTZBERG, C.L.; ALTHOF, V.G.M.; HUIZENGA, H.; VISSER, A.G. & LEVENDAG, P.C. (1993), Quality assurance using portal imaging: the accuracy of patient positioning in irradiation of breast cancer., International journal of radiation oncology, biology, physics.
- CREUTZBERG, C.L.; VISSER, A.G.; DEPORRE, P.M.Z.R.; MEERWALDT, J.H.; ALTHOF, V.G.M. & LEVENDAG, P.C. (1992), ACCURACY OF PATIENT POSITIONING IN MANTLE FIELD IRRADIATION, Radiotherapy and Oncology 23(4): 257-264.
- CL C, PP J & JW M (1989), [Visit to the emergency department: primary or secondary character?], Nederlands Tijdschrift voor Geneeskunde.
- Schelfhout LJ, Creutzberg CL, Hamming JF, Fleuren GJ, Smeenk D, Hermans J, van de Velde CJ & Goslings BM (1988), Multivariate analysis of survival in differentiated thyroid cancer: the prognostic significance of the age factor., European journal of cancer & clinical oncology 24(2): 331-7.
- BROMBERG, J.E.C.; CREUTZBERG, C.L. & ATHERTON, D.J. (1985), SWEAT PRODUCTION IN CHILDRENS FEET, Clinical and Experimental Dermatology 10(3): 229-232.
- Bestuurslid
- Council member
- Lid concilium